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Abstract 
 I 
ABSTRACT 
 
Lysosomal storage disorders (LSDs) are a group of neurometabolic syndromes, 
mostly due to the deficit of one lysosomal enzyme. Many LSDs affect most of the 
organ systems and about two-thirds of the patients also present neurological 
and cognitive impairment. Enzyme replacement therapy, the most common 
therapeutic strategy applied to some LSDs, although determining some clinical 
improvements, has revealed to be ineffective on the CNS disease, due to 
enzymes' inability to cross the blood-brain barrier (BBB). So alternative methods 
to achieve transcytosis into the CNS need to be explored. 
Among LSDs, Mucopolysaccharidoses (MPS) are characterized by a totally or 
partially defective activity of lysosomal enzymes involved in the catabolism of 
the glycosaminoglycans (GAGs), which, therefore, heavily accumulate within 
cellular compartment and in the extracellular matrix. 
In this study, in which MPS type I and type II have been in particular evaluated, 
polymeric nanoparticles (NPs), modified with a glycopeptide of 7 amino acids 
(g7), already tested for the delivery of low molecular weight molecules, were 
tested as possible vehicle for BBB crossing and delivering of the therapeutic 
recombinant enzymes to the CNS after systemic administration in mice. 
Results obtained in preliminary studies in the MPS I and MPS II mouse models, 
clearly showed that g7-NPs are able to deliver the model drug FITC-albumin to 
the brain, by crossing the BBB, in all treated mice (Idua-ko, Ids-ko and wt).  
The subsequent in vivo preliminary study in the MPS II mouse model, using g7-
NPs loaded with the recombinant IDS enzyme and labelled with Rhodamine B 
(g7-NPs-IDS-R), confirmed that g7-NPs can transport the enzyme through the 
BBB and paved the way for the upcoming in vitro and in vivo efficacy studies. 
In the in vitro study fibroblasts obtained from MPS II patients were treated with 
untargeted NPs (devoid of g7), loaded with the recombinant enzyme for MPS II. 
Data obtained suggested that nanoparticles may need more than 2 weeks to 
open up and release the recombinant enzyme or, otherwise, that they may need 
a more complex physiological system with respect to the in vitro one. 
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To evaluate transfer efficiency and the enzymatic activity induced by g7-NPs 
loaded with the recombinant enzyme (g7-NPs-IDS), an in vivo pilot study in the 
MPS II mouse model was conducted. Mice were treated with a single dose of 
enzyme and sacrificed after 7 or 14 days. No induced IDS activity or reduction in 
GAG storage was, however, detected in liver and brain of g7-NPs-IDS treated 
mice.  
Although the results obtained in the in vitro and in vivo pilot studies were mostly 
negative, it was important to carry out a medium-term analysis to assess the 
possible opening of NPs in a longer time. To this aim, an in vivo study was 
conducted in the MPS II mouse model, by treating mice once a week for 6 weeks. 
Biochemical, histological, immunohistochemical and immunofluorescence 
evaluations, conducted in liver and brain of g7-NPs-IDS treated mice suggested 
that a period of 6 weeks is again too short to detect the opening of the NPs and 
the release of the encapsulated enzyme. However, results obtained from this 
medium-term study are encouraging as they show a slight trend towards 
improvement in brain and liver of g7-NPs-IDS treated mice. 
Further studies, at the moment ongoing, are needed to understand the timing of 
release of the enzyme from the NPs; in addition, we are re-formulating the 
nanoparticles with the aim to maintain the same transport efficiency to the CNS, 
although allowing a significant reduction of the timing of drug release. 
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RIASSUNTO 
 
Le malattie da accumulo lisosomiale (LSD) sono un gruppo di patologie 
neurometaboliche, causate principalmente dal deficit di un enzima lisosomiale. 
Le LSD sono malattie multisistemiche e circa due terzi dei pazienti presentano 
anche danno neurologico e cognitivo. La terapia enzimatica sostitutiva, la 
strategia terapeutica più comunemente applicata ad alcune LSD, pur 
determinando alcuni miglioramenti sistemici, si è rivelata inefficace nel 
trattamento del coinvolgimento neurologico, a causa dell’incapacità degli enzimi 
terapeutici di attraversare la barriera emato-encefalica (BEE). Diventa, perciò, di 
primaria importanza valutare metodi alternativi per il trasporto di questi farmaci 
al sistema nervoso centrale (SNC). 
Tra le LSD, le Mucopolisaccaridosi (MPS) sono caratterizzate dalla mancanza 
totale o parziale di attività di enzimi lisosomiali coinvolti nel catabolismo dei 
glicosaminoglicani (GAG), che, pertanto, si accumulano sia nel comparto cellulare 
che nella matrice extracellulare.  
In questo studio, nel quale sono state in particolare studiate le MPS di tipo I e di 
tipo II, nanoparticelle polimeriche (NPs), modificate con un glicopeptide di 7 
amminoacidi (g7), già testate per il trasporto oltre barriera di molecole a basso 
peso molecolare, sono state valutate come possibile veicolo per 
l’attraversamento della BEE e il trasporto degli enzimi terapeutici ricombinanti al 
SNC, dopo somministrazione sistemica nei topi. 
I risultati ottenuti negli studi preliminari nei modelli murini per la MPS I e la MPS 
II, hanno mostrato chiaramente che le g7-NPs sono in grado di trasportare al 
cervello l’albumina-FITC (farmaco modello), attraversando la BEE, in tutti i topi 
trattati (Ids-ko, Idua-ko e wt). 
Il successivo studio preliminare in vivo nel modello murino per la MPS II, in cui 
sono state testate le g7-NPs caricate con l’enzima IDS ricombinante e marcate 
con Rodamina B (g7-NPs-IDS-R), ha confermato che le g7-NPs sono in grado di 
trasportare l’enzima attraverso la BEE, aprendo così la strada per i successivi 
studi di efficacia da effettuare in vitro ed in vivo. 
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Nello studio in vitro, fibroblasti ottenuti da pazienti affetti da MPS II sono stati 
trattati con NPs non targettate (prive di g7) e caricate con l’enzima ricombinante 
impiegato per la terapia di questa patologia. I dati ottenuti hanno suggerito che 
le nanoparticelle probabilmente necessitano di un tempo superiore alle 2 
settimane per aprirsi e rilasciare l’enzima ricombinante o, anche, che le fasi di 
apertura e rilascio potrebbero necessitare di un sistema fisiologico più complesso 
rispetto ad un sistema in vitro. 
Per valutare l'efficienza di trasferimento e l'attività enzimatica indotta dalle g7-
NPs caricate con l'enzima ricombinante (g7-NPs-IDS), è stato di seguito condotto 
uno studio pilota in vivo nel modello murino per la MPS II. I topi sono stati 
trattati con una singola dose di enzima e sacrificati dopo 7 o 14 giorni. Nel fegato 
e nel cervello dei topi trattati con g7-NPs-IDS non è stata, tuttavia, rilevata 
alcuna attività IDS indotta o la riduzione dei depositi di GAG. 
Sebbene i risultati ottenuti dallo studio in vitro e da quello pilota in vivo 
risultassero per lo più negativi, era importante effettuare un’analisi a medio 
termine per valutare l’eventuale apertura delle NPs in un tempo più lungo. A 
questo scopo, è stato condotto uno studio in vivo nel modello murino per la MPS 
II, mediante somministrazione settimanale di NPs nei topi, per un totale di 6 
settimane. Le valutazioni biochimiche, istologiche, immunoistochimiche e di 
immunofluorescenza condotte nel fegato e nel cervello dei topi trattati con le g7-
NPs-IDS hanno evidenziato che un periodo di 6 settimane di trattamento è 
ancora insufficiente per consentire un'efficace apertura delle NPs e il rilascio 
dell’enzima incapsulato. Tuttavia, i risultati ottenuti da questo ultimo studio a 
medio termine sono risultati incoraggianti, poiché mostrano una costante, se pur 
lieve, tendenza al miglioramento nel fegato e nel cervello dei topi trattati con g7-
NPs-IDS. 
Ulteriori studi sono necessari, e sono attualmente in corso, per capire i tempi di 
rilascio dell’enzima dalle NPs; inoltre, è in fase di rivalutazione la formulazione 
delle stesse, con l'obiettivo di mantenerne l'efficienza di trasporto al SNC, ma di 
ridurne i tempi di rilascio del farmaco. 
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1. INTRODUCTION 
 
1.1 LYSOSOMAL STORAGE DISEASES 
Lysosomal storage diseases (LSDs) are a group of about 60 different inherited 
metabolic disorders caused by deficiencies in lysosomal hydrolases, lysosomal 
membrane proteins or lysosomal transporters, resulting in abnormal 
accumulation of undegraded metabolites and dysregulation of lysosomes. 
Individually rare, LSDs have a prevalence ranging from 7.6 to 26.9 per 100,000 
live births (Meikle et al., 1999; Poorthuis et al., 1999; Applegarth et al., 2000; 
Pinto et al., 2004; Fuller et al., 2006; Spada et al., 2006; Poupetova et al., 2010; 
Mechtler et al., 2012; Al-Jasmi et al., 2013; Scott et al., 2013; Hult et al., 2014). 
Although many LSDs had already been recognized as clinical entities since the 
19th century, their classification was born many years later with the discovery of 
the lysosome by Christian de Duve in 1955 (de Duve C et al., 1955) and with the 
development of the concept of lysosomal diseases by Hers in 1965 (Hers HG, 
1965). 
Typically, LSDs are classified based on the nature of the storage material or on 
the defective lysosomal protein: mucopolysaccharidoses, mucolipidoses, 
glycolipidoses and glycoproteinoses (Alroy J et al., 2014). 
Lysosomes are membrane-bound cytoplasmic organelles containing acid 
hydrolases, enzymes that degrade a variety of macromolecules as part of normal 
cellular function. A lysosomal defect, most commonly a mutation in genes that 
encode catalytic enzymes, results in accumulation of undegraded material 
causing cell and organ dysfunction; however, the mechanisms by which the 
storage leads to the disease are not well understood. To explain this, in the past 
25 years many investigations have been carried out, realizing that there are 
many factors playing a role in the pathophysiology of LSDs, including alterations 
of intracellular calcium homeostasis, impairment of autophagy, activation of 
signal transduction by non-physiological substances, inflammation, and others 
(Ballabio A and Gieselmann V, 2009). 
1. Introduction 
 2 
All LSDs are monogenic disorders, inherited as autosomal recessive traits except 
for Fabry disease, Hunter Syndrome and Danon disease, which are X-linked 
conditions. Numerous mutations in the same gene in different patients have 
been described, including missense, nonsense and splice-site mutations, partial 
deletions and insertions. Some mutations lead to the complete loss of enzyme 
activity, whereas others lead to reduced activity. However, no obvious 
genotype–phenotype correlation has been found and prediction of the clinical 
course of the disease cannot usually be made based on mutational analysis. 
(Futermann and van Meer, 2004). 
 
1.2 GLYCOSAMINOGLYCANS 
Glycosaminoglycans (GAGs) or mucopolysaccharides are long unbranched 
molecules consisting of a repeating disaccharide unit. The repeating unit (except 
for keratan) consists of an amino sugar (N-acetylglucosamine or N-
acetylgalactosamine) along with an uronic sugar (glucuronic acid or iduronic acid) 
or galactose. The specific monosaccharide units identify the subtype of GAG. 
Four main groups of GAGs are classified based on their sugar, the type of linkage 
between them and the number and location of sulfate groups: hyaluronan, 
chondroitin sulfate (CS), dermatan sulfate (DS), heparan sulfate (HS), keratan 
sulfate (KS) (Alberts et al., 2002). With the exception of hyaluronic acid, all GAGs 
contain sulfate groups. 
GAGs are involved in the formation of the extracellular matrix, adhesion, cell 
differentiation and growth, as well as apoptosis. 
The degradation of GAGs is catalysed by lysosomal hydrolytic enzymes, exo- and 
endo-glycosidases, which act sequentially. Catabolism always proceeds from the 
not-reduced end by glycosidases and sulfatase. Figure I shows the degradative 
cascade of heparan, keratan, dermatan and chondroitin sulfate. 
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Figure I: GAG degradation pathway and the blockage of each enzyme leading to different types of 
mucopolysaccharidoses. Abbreviations: I2S, iduronate-2-sulphatase; IDUA, alpha-L-iduronidase; 
SGSH, heparan N-sulphatase; HGSNAT, acetyl-CoA:alpha-glucosaminide N-acetyltransferase; 
NAGLU, N-acetyl-alpha-glucosaminidase; GUSB, beta-glucuronidase; GNS, N-acetylglucosamine 6-
sulphatase; ASB, N-acetylgalactosamine 4-sulphatase; GALNS, N-acetylgalactosamine-6-sulphate 
sulphatase; GLB1, beta-galactosidase (adapted from Noh and Lee, 2014). 
 
1.3 MUCOPOLYSACCHARIDOSES 
Mucopolysaccharidoses (MPSs) are a group of lysosomal storage disorders 
caused by deficiency of enzymes catalysing the degradation of 
glycosaminoglycans (or mucopolysaccharides). Depending on the enzyme 
deficiency, the catabolism of dermatan sulfate, heparan sulfate, keratan sulfate, 
chondroitin sulfate or hyaluronan may be blocked, singly or in combination 
(Neufeld and Muenzer, 2001). 
Deficiency of one of these enzymes leads to development of one of eleven types 
and subtypes of MPSs (Table I). 
 
 
Heparan	Sulfate	 Dermatan	Sulfate	 Keratan	Sulfate	 Chondroi n	Sulfate	
Degrada on	
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Degrada on	
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Degrada on	
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Degrada on	
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I2S	
IDUA	
SGSH	
HGSNAT	
NAGLU	
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GNS	
I2S	
IDUA	
ARSB	
GUSB	
GALNS	
GLB1	 GUSB	
GALNS	
ASB	
X
X
X
X
X
X
X
X
X
X
X
X
X X
X
X
MPS	II	
MPS	I	
MPS	IIIA	
MPS	IIIC	
MPS	IIIB	
MPS	VII	
MPS	IIID	
MPS	II	
MPS	I	
MPS	VI	
MPS	VII	
MPS	IVA	
MPS	IVB	 MPS	VII	
MPS	IVA	
MPS	VI	
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Pathology OMIM Gene Localization Enzyme deficiency 
GAG storage 
material 
ERT 
MPS I (Hurler, 
Hurler-Scheie, 
Scheie) 
607014 
607015 
607016 
IDUA 4p16.3 α-L-Iduronidase 
Dermatan 
sulphate, 
heparan sulphate 
Aldurazyme® 
MPS II (Hunter) 309900 IDS Xq28 Iduronate 2-sulfatase 
Dermatan 
sulphate, 
heparan sulphate 
Elaprase® 
MPS IIIA 
(Sanfilippo A) 
252900 SGSH 17q25.3 Heparan-N-sulfatase Heparan sulphate  
MPS IIIB 
(Sanfilippo B) 
252920 NAGLU 17q21.2 α-N-acetylglucosaminidase Heparan sulphate  
MPS IIIC 
(Sanfilippo C) 
252930 HGSNAT 8p11.21 
Heparan acetyl-CoA: α-
glucosaminide N-
acetyltransferase 
Heparan sulphate  
MPS IIID 
(Sanfilippo D) 
252940 GNS 12q14.3 
N-acetylglucosamine 6-
sulfatase 
Heparan sulphate  
MPS IVA 
(Morquio A) 
253000 GALNS 16q24.3 Galactose 6-sulfatase 
Keratan sulphate, 
chondroitin 
sulphate 
Vimizim® 
MPS IVB 
(Morquio B) 
253010 GLB1 3p22.3 β-Galactosidase Keratan sulphate  
MPS VI 
(Maroteaux-
Lamy) 
253200 ARSB 5q14.1 
Arylsulfatase B (N-
acetylglucosamine 4-
sulfatase) 
Dermatan 
sulphate, 
chondroitin 
sulphate 
Naglazyme® 
MPS VII (Sly) 253220 GUSB 7q11.21 β-Glucuronidase 
Dermatan 
sulphate, 
heparan 
sulphate, 
chondroitin 
sulphate 
 
MPS IX 
(Natowicz) 
610492 HYAL 3p21.31 Hyaluronidase Hyaluronan  
Table I: MPSs classification with related OMIM code, gene symbol, localization on chromosome, 
enzyme deficiency, GAG storage material and, where available, the enzyme replacement therapy 
(ERT).  
 
1.3.1 History 
The first clinical characterization of a mucopolysaccharide disorder dates back to 
1917 when Charles Hunter defined the clinical profile of a patient now 
identifiable as affected by MPS II (Hunter, 1917) and subsequently, in 1929, Luis 
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Morquio described four children affected by a condition now recognized as MPS 
IV (Morquio, 1976). 
The very big thrust to MPS survey was, doubtless, the discovery of the lysosome 
during the ‘50s by Christian de Duve (de Duve et al., 1955), which allowed the 
settlement of the other MPS profiles and, above all, enabled a better 
understanding of the pathophysiology and of the basic biochemical processes 
involved in the disease onset. 
However, the term MPS was suggested in 1952, after the identification of 
excessive amounts of GAGs in samples from patients with Hurler syndrome 
(Brante, 1952; Dorfman and Lorincz, 1957). Only in 1964 appeared the concept 
of MPSs as enzymatic deficiencies, when van Hoof and Hers proposed that these 
disorders were analogous to Pompe disease and therefore, due to specific 
lysosomal hydrolase deficiencies. Supporting this idea were the results from 
these two authors, who observed dramatically enlarged lysosomes in Hurler 
hepatocytes (Van Hoof and Hers, 1964) and, four years later, the studies 
conducted by Fratantoni and co-workers.; together, these experiments have 
demonstrated impaired GAG degradation (Fratantoni et al., 1968). 
In 1966 McKusick first categorized MPS disorders in six defined groups based on 
clinical traits and genetic and biochemical findings (McKusick, 1966). 
 
1.3.2 Genotype and Phenotype  
With the exception of MPS II, which is X-linked, the MPS disorders are inherited 
in an autosomal recessive manner and affect both males and females equally. 
Mutations underlying these diseases are extremely heterogeneous, often 
private, but one or a few mutated alleles may predominate in specific 
populations ("hot spots"). Most are point mutations or small changes in the 
gene, although large rearrangements and deletions can occur in MPS II. 
Genotype-phenotype correlation is sometimes possible, but the effect of 
missense mutations is generally difficult to predict (Neufeld and Muenzer, 2001). 
MPSs are chronic and progressive syndromes that produce a spectrum of signs 
and symptoms in multiple organ systems. Patients typically appear normal at 
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birth, but during early childhood they experience the onset of clinical signs and 
symptoms including organomegaly, skeletal, joint, airway and cardiac 
involvement, hearing and vision impairment, and progressive cognitive delay in 
the severe forms of MPS I, MPS II and MPSVII and all subtypes of MPS III 
(Muenzer, 2011). 
The overall prevalence of MPSs is difficult to assess because of the lack of 
epidemiological studies; the known values are shown in Table II. 
 
Disease 
Prevalence per 100,000 live births 
Poland 
The 
Netherlands 
Germany Australia Norway Denmark Sweden 
Czech 
Republic 
Italy 
MPS I 0.22 1.19 0.69 - 1.85 0.54 0.67 0.72 - 
MPS II 0.46 0.67 0.64 0.31 0.13 0.27 0.27 0.43 1.21 
MPS III (all 
type) 
0.86 1.89 1.57 1.71 0.27 0.43 0.67 0.91 - 
MPS IV 
(A+B) 
0.14 0.36 0.38 0.15 (A) 0.76 0.48 0.07 0.73 - 
MPSVI 0.0132 0.15 0.23 0.31 0.07 0.05 0.07 0.05 - 
MPSVII 0 0.24 0 - - - - 0.02 - 
MPS IX 0 - 0 - - - - - - 
MPS all 
types 
1.81 4.5 3.53 3.34 3.08 1.77 1.75 3.72 2.45 
Table II: Prevalence of mucopolysaccharidoses per 100,000 live births: comparison of data in 
different populations (adapted from Jurecka et al., 2014; Dionisi-Vici et al., 2002). 
 
1.3.3 Diagnosis 
Early diagnosis of MPSs is of extreme importance to optimize treatment and 
outcomes, particularly for those disorders that are amenable to treatment with 
HSCT or ERT. 
Not rarely the diagnosis of MPSs takes several months or years from the onset of 
the first symptoms, thus reducing the benefits of the available therapies 
(Marsden and Levy, 2010). This delay is caused by the difficult differential 
diagnosis and by the fact that MPSs, being rare, are not clinically well known. To 
confirm an MPS clinical suspect, the first laboratory step is the urinary GAG 
quantification and qualitative analysis. If GAG level is high and/or the qualitative 
spectrum is strongly suggestive, an enzymatic analysis is carried out in plasma or 
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peripheral leukocytes or cultured cells. Finally, the enzymatic deficit 
identification is confirmed by the molecular analysis of the corresponding gene.  
At the beginning of the last decade Chamoles and coworkers introduced the 
Dried Blood Spots (DBSs) analysis for the enzymatic diagnosis of several 
lysosomal storage disorders including some MPSs (Chamoles et al., 2001a, 
2001b). The use of DBSs to perform enzyme assays offers several advantages, 
among others little invasiveness and the requirements of extremely small 
amounts of blood, rendering the analysis possible even in the case of newborns, 
thus allowing pre-symptomatic diagnosis (Gasparotto et al., 2009). Since 2004 a 
new method combining the advantage of using DBSs for samples collection, and 
the high sensitivity and selectivity of tandem mass spectrometry (MS/MS) for the 
analysis, has been developed (Li et al., 2004). The procedure is having a great 
success, as it is suitable for high throughput and multiplex analysis of several 
enzymes simultaneously in hundreds of samples; however, ethical reasons 
suggest their application only to screen diseases for which a therapy is available. 
 
1.3.4 Therapies 
 
1.3.4.1 Enzyme replacement therapy 
Enzyme Replacement Therapy (ERT) is based on the intravenous infusion of a 
recombinant human enzyme. The drug is internalized via mannose 6-phosphate 
(M6P) receptors, reaches its target site in the lysosomes and replaces the 
defective lysosomal enzyme (Noh and Lee, 2014).  
To date, the FDA and the EMEA have approved 4 recombinant human enzymes 
for MPSs: laronidase (Aldurazyme®, Genzyme Corporation) for MPS I, idursulfase 
(Elaprase®, Shire Human Genetics Therapies Inc.) for MPS II, galsulfase 
(Naglazyme®, BioMarin Pharmaceutical Inc.) for MPSVI and, recently, elosulfase 
alpha (Vimizim®, BioMarin Pharmaceutical Inc.) for MPS IVA. 
Although systemic manifestations partly ameliorate with ERT, the treatment has 
no effect on bone, heart valves and CNS disease (Noh and Lee, 2014). In fact, the 
low level of the BBB transport system for acid hydrolases and the high molecular 
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weight of these enzymes make any paracellular or transcellular diffusion of these 
proteins across the BBB almost non-existent. Therefore, efficient methods to 
achieve a safe transcytosis into the CNS need to be explored. 
 
1.3.4.2 Hematopoietic stem cell transplantation 
Hematopoietic stem cell transplantation (HSCT) with bone marrow or umbilical 
cord stem cells has been revealed to prevent many clinical features of the severe 
phenotypes of MPS I, VI and VII. Furthermore, in very young MPS I patients 
(earlier than 2.5 years), HSCT can significantly preserve intellectual development, 
differently to what happens for MPS II and MPS III. Of great importance, HSCT 
success depends on the age of the child, the degree of clinical involvement and 
the ability to achieve stable engraftment. Moreover, the procedure still 
maintains a significant risk of morbidity and mortality (Cimaz and La Torre, 
2014). 
 
1.3.4.3 Substrate reduction therapy 
The principle of substrate reduction therapy (SRT) is to reduce the amount of 
storage material into the compromised lysosome by partially inhibiting the 
biosynthetic cycle instead of enhancing the activity of the degrading enzymes. 
Since these strategies generally propose the use of low molecular weight 
molecules able to cross the BBB, their administration in MPSs are expected to 
obtain a treatment of the brain compartment. 
The first SRT protocol for MPSs was proposed in 2006 by Roberts and colleagues 
(Roberts et al., 2006); the use of rhodamine B reduced the lysosomal storage in 
MPS cells and demonstrated in vivo in MPS IIIA mice the ability of the molecule 
to reverse clinical parameters of disease progression. However, rhodamine B 
could not be used in clinical treatments due to its possible toxic effects 
(Jakobkiewicz-Banecka et al., 2009). 
Since 2006 another molecule has been proposed to inhibit GAG synthesis, 
genistein (4’,5,7- trihydroxyisoflavone or 5,7-dihydroxy-3-(4-hydroxyphenyl)-4H-
1-benzopyran-4-one), an isoflavone more commonly used for menopause 
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(D'Anna et al., 2009), cardiovascular disease (Vera et al., 2007) and osteoporosis 
(Wang et al., 2006). It was shown to inhibit GAG synthesis in cultured fibroblasts 
obtained from different MPS patients (Piotrowska et al., 2006). Moreover, in a 1 
year open-label pilot study performed in MPS III patients, improvements in 
urinary GAG excretion, hair morphology and cognitive function was reported 
(Piotrowska et al., 2008); however these results were not confirmed by a 
subsequent study by Delgadillo and colleagues (Delgadillo et al., 2011). In vivo 
preclinical studies have shown efficacy of genistein in MPS IIIB (Malinowska et 
al., 2009, 2010) and MPS II mice (Friso et al., 2010). However, an improvement in 
CNS correction and mice behaviour was only obtained following administration 
of very high dosages of genistein (Malinowska et al., 2010), about 30-fold higher 
than the dosage commonly suggested for patients. 
 
1.3.4.4 Gene therapy 
Human gene therapy consists in the insertion of normal DNA directly into cells to 
provide a stable source of the defective enzyme. It has the advantage to reach 
both the brain and the skeletal structures. The main problem is to find a safe 
vector that results in therapeutic levels of gene expression. 
Many approaches have been tested for MPSs, both viral and non viral, in vivo 
and ex vivo (Tomanin et al., 2012). The in vivo approach is the most studied. In 
particular, intracerebral gene therapy represents a promising approach, as it 
could be a permanent source of the functional form of the enzyme directly on 
the CNS. To underline that, in LSDs enzyme activity just equal to 5-10% of the 
normal level was described as sufficient to obtain an effect in the deficient cells 
(Sands et al., 2006; Calias et al., 2012). 
However, although the data obtained so far are encouraging, there are still 
limitations that must be overcome to ensure the success of these new 
therapeutic approaches. Among these, we need a greater understanding of the 
biology and pathophysiology of MPSs and the possible toxicity and immune 
response related to gene transfer (Seregin et al., 2011). Interesting will be the 
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results generated by the trials ongoing for MPS IIIA and IIIB involving the 
intrathecal injection of an adeno-associated virus. 
 
1.3.4.5 Intrathecal injection 
The direct transfer of the recombinant enzyme in CSF effectively reduces the 
accumulation of non-degraded metabolites in the brain parenchyma 
(Valayannopoulos et al., 2011). Experiments in animal models of 
mucopolysaccharidosis type I, II and IIIA have demonstrated that intrathecal ERT 
injection is able to distribute the recombinant enzyme throughout the central 
nervous system, to penetrate the brain tissue and to promote the clearance of 
accumulated material within the lysosomes (Dickson, 2009). 
To date, the challenge is to translate to the patient the success so far obtained 
on large and small animals. Therefore, protocols for the intrathecal injection of 
enzyme for MPSs and other LSDs are currently the subject of clinical trials 
(Dickson et al., 2011). 
Intrathecal lumbar enzyme replacement is presently under clinical trial in 
patients with MPS I (NCT#00852358), MPS II (NCT#00920647; #01506141) and 
MPS IIIA (NCT#01155778; #01299727). At the moment, only the results obtained 
from the administration of a very small sample of patients with MPS I and MPS VI 
are available (Dickson et al., 2009, 2011; Giugliani et al., 2011). Despite being at 
present the only promising approach to the treatment of the neurological 
manifestations of LSD, intrathecal enzyme therapy should be modified in the 
procedure of its administration. Indeed, the administration throughout life of the 
enzyme by an intrathecal catheter is unfeasible. The catheter is an artificial 
opening of the BBB and a possible source of infection. Moreover, agitation, 
aggression and hyperexcitability of MPS children with neurological involvement 
have already prompted changes to catheters currently used in clinical trials. For 
these reasons, modified enzymes able to cross the BBB are currently under 
preclinical studies (Scarpa et al., 2012). 
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1.4 MUCOPOLYSACCHARIDOSIS TYPE I 
Mucopolysaccharidosis type I (MPS I) is a metabolic inherited disorder due to the 
deficit of the lysosomal enzyme α-L-iduronidase (IDUA), involved in the 
degradation of the glycosaminoglycans heparan- and dermatan-sulfate (Figure I).  
Clinical symptoms and pathological features of the disorder, including heart 
disease, corneal clouding, organomegaly, skeletal malformations and joint 
stiffness, are due to the progressive accumulation of undegraded GAG in the cell 
lysosomes (Neufeld and Muenzer, 2001). 
Historically MPS I has been divided into three different pathologies on the basis 
of clinical manifestations: Hurler syndrome (severe form, OMIM #607014), also 
characterized by a heavy neurological involvement; Hurler-Scheie syndrome 
(intermediate, OMIM #607015); Scheie syndrome (mild, OMIM #607016, 
previously called MPS V). 
Occurrences of the three different phenotypes from the global MPS I registry are 
shown in Table III. 
 
Geographic region Hurler (%) Hurler-Scheie (%) Scheie (%) Undetermined (%) 
All regions 60.9 23.0 12.9 3.2 
Asia Pacific 29.2 20.8 50.0 0 
Europe 61.5 22.7 14.0 1.8 
Latin America 42.7 33.3 12.9 11.1 
North America 71.4 18.4 8.7 1.5 
Table III: Distribution of MPS I phenotypes by geographic region (adapted from Beck et al., 2014) 
 
1.4.1 Genetics 
The gene coding for the enzyme alpha-L-iduronidase (IDUA, EC 3.2.1.76) maps on 
4p16.3. It has a length of 19492 bp and consists of 14 exons; repeated Alu 
sequences and highly polymorphic VNTR sequences were found in exon 2 (Scott 
et al., 1992, 1995). The cDNA consists of an open reading frame (ORF) of 2138 bp 
encoding the protein IDUA, formed by 653 amino acids and with 6 sites of N-
glycosylation (Zhao et al., 1997). 
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MPS I is inherited in an autosomal recessive manner. Until now, 212 different 
mutations have been identified in this gene, including nonsense, missense and 
spilicing mutations, deletions and insertions. Up to 70% of mutations are 
recurrent and thus may be helpful in phenotype prediction; however, a 2003 
comprehensive review of genotype-phenotype correlations illustrates the 
limitations related to the frequency of private mutations at this locus (Terlato & 
Cox, 2003, Bertola et al., 2011; Wang et al., 2012). Moreover, a 2011 study has 
underlined the existence of dramatic differences in mutational heterogeneity 
and mutation prevalence highlights the importance of multi-national screening 
studies in helping to elucidate the genotype-phenotype relationship (Bertola et 
al., 2011). 
The most common mutations in Caucasians are W402X and Q70X; they encode 
for prematurely stop codons, giving rise to particularly severe forms of MPS I, 
and in some countries are responsible for over 70% of cases of MPS I (Gort et al., 
1998; Beesley et al., 2001).  
Most of the mutations leading to the intermediate and attenuated form of MPS I 
are missense and allow the synthesis of minimum levels of IDUA (Tieu et al. 
1995). 
 
1.4.2 Clinical features 
Hurler syndrome (MPS I/H): The most severe MPS I phenotype is characterized by 
impaired cognitive development, hepatosplenomegaly, cardiac valvulopathy, 
corneal clouding, progressive coarsening of facial features, respiratory failure, 
recurrent otitis media, musculoskeletal manifestations such as joint stiffness and 
contractures, dysostosis multiplex (Figure II). The symptoms arise after birth and 
progress rapidly. Most of the patients die before 10 years of age if untreated, 
due to complications related to brain damage or cardiorespiratory problems 
(Pastores et al., 2007; Soliman et al., 2007). 
Hurler-Scheie syndrome (MPS I H/S): This phenotype manifests in infancy with 
intermediate severity compared with Hurler phenotype. Generally, there is no 
cognitive impairment, but some patients may exhibit mild learning difficulties. 
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Life expectancy is reduce to the second or third decade of life (Pastores et al., 
2007; Soliman et al., 2007).  
Scheie syndrome (MPS I/S): This is the most attenuated form (Soliman et al., 
2007), symptoms occur later and progress slowly, rarely is diagnosed in 
childhood. Generally, patients exhibit normal intelligence and survive until 
adulthood (Pastores et al., 2007). 
 
Figure II: Aspect of a child with MPS I (from “MPS I, a disease with many faces” - Genzyme 
Corporation, 2004) 
 
1.4.3 Therapies 
 
1.4.3.1 Hematopoietic Stem Cell Transplantation 
The hematopoietic stem cell transplantation (HSCT) is still the treatment of 
choice for the severe form of MPS I, especially if performed before the onset of 
damage to the different organs (Guffon et al., 1998). It may include bone marrow 
transplantation (BMT), peripheral blood or umbilical cord transplantation. 
To date the best results have been obtained with BMT, since it generates a 
renewed source of enzyme, able to correct the accumulation of GAGs in the 
different districts of the organism (Guffon et al., 1998). Therefore, BMT slows 
down the progress of the disease and in patients with the attenuated forms also 
allows the preservation of cognitive development. 
The first allogeneic BMT for MPS I has been successfully performed in 1981 by 
Hobbs and co-workers on a one year-old baby, suffering from the severe form of 
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the disease. Thirteen months later, the patient showed an activity of α-L-
iduronidase similar to that of heterozygotes, with regression of 
hepatosplenomegaly and corneal opacification and with arrest in the progression 
of the other degenerations (Hobbs et al., 1981). 
Since then, more than 1000 patients with the severe form of MPS I have been 
transplanted and, where the graft was successful, restoration of enzymatic 
function and subsequent amelioration of disease complications has been 
obtained. If HSCT is performed before the age of 2.5 years and before the onset 
of serious mental involvement, joint mobility, vision, hearing and 
cardiopulmonary functions have been shown to improve, cognition preserved 
and survival increased. However, benefit in bone and cornea is limited and, 
above all, the risks of morbidity and mortality associated with HSCT remain 
significant (Noh and Lee, 2014). Therefore, HSCT should be considered only after 
careful consideration and only in very young patients before the onset of 
symptoms. 
 
1.4.3.2 Enzyme Replacement Therapy – Aldurazyme ® 
Laronidase (recombinant human α-L-iduronidase, Aldurazyme®; Genzyme 
Corporation, Cambridge, MA and BioMarin Pharmaceutical, Inc., Novato, CA, 
USA) was the first ERT drug approved for treatment of an MPS disorder and has 
been available in the USA and Europe since 2003. It is a polymorphic variant of 
the human enzyme alpha-L-iduronidase, with a molecular weight of 83 kDa. It is 
produced by recombinant DNA technology in a Chinese hamster ovary cell line. 
The recommended dose is 0.58 mg/kg (100 U/kg) administered by intravenous 
infusion over 4 hours once a week, but a double dose every 2 weeks could be an 
acceptable alternative regimen for patients who have difficulty receiving weekly 
infusions (Giugliani et al., 2009). 
ERT for MPS I became possible only after the cloning of the IDUA gene (Scott et 
al., 1992) and its high-level expression in a stable clone of CHO cells (Kakkis et al., 
1994). After many preclinical studies, several clinical trials have demonstrated 
that ERT with laronidase is safe and effective in patients with MPS I, across a 
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wide range of ages (young children to adults) and disease severity(Kakkis et al., 
2001; Wraith et al., 2004, 2007; Clarke et al., 2009; Giugliani et al., 2009; Beck et 
al., 2014). Results of clinical trials have demonstrated the efficacy of ERT in 
reducing hepatosplenomegaly and urinary GAG levels, increasing distance 
walked in the 6-min walk test, stabilizing or improving joint range motion, 
stabilizing or decreasing sleep apnoea, decreasing left ventricular hypertrophy 
and improving the quality of life. However, the results of the clinical trials, have 
revealed that some symptoms of the disease are not reversible, particularly 
heart, bone and joint disease and corneal opacification. Moreover, laronidase 
cannot cross BBB and correct the neurological involvement in subjects with 
severe forms. These studies have also shown an immune response against the 
recombinant protein, with a peak in the production of IgG after 12 weeks of 
treatment. A recent study has demonstrated that antibodies significantly reduce 
enzyme uptake with negative consequences on its efficacy (Langereis et al., 
2014). 
 
1.4.3.3 Other therapies 
At present, studies are focused on the development of new forms of therapy 
directed to areas and organs that do not respond to ERT. Alternative routes of 
administration and modifications of the enzyme to reach the central nervous 
system are the main focus, as IDUA cannot cross the blood brain barrier. 
Intrathecal ERT, tested in animals and already reported in a few patients, may 
become a tool to treat or prevent the CNS manifestations in the severe forms of 
MPS I, but, as noted earlier in section 1.3.4.5, it presents several limitations (Vera 
et al., 2013).  
Another therapeutic strategy is represented by the stop-codon read-through 
(SCRT), which has been tried in preclinical studies for MPS I and could be a 
potential tool for a large subgroup of patients with nonsense mutations. The 
capability of chloramphenicol to suppress the stop-codon has been analysed in 
human MPS I fibroblasts carrying different nonsense mutations, obtaining 
increased IDUA activity in all tested fibroblasts (Mayer et al., 2013). 
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Recent in vivo studies have also evaluated the possibility of encapsulating the 
enzyme in microcapsules (Piller Puicher et al., 2012) or modifying it with 
appropriate molecules such as ApoE (El-Amouri et al., 2014) 
Many preclinical studies with various type of vector and in different animal 
models (mouse, cat, dog, monkey) were conducted to investigate gene therapy, 
but, even if presented with quite encouraging results, this treatment modality 
took a long time to move forward into clinical studies (Giugliani et al., 2012). 
 
1.5 MUCOPOLYSACCHARIDOSIS TYPE II 
Mucopolysaccharidosis type II or Hunter Syndrome (MPS II; OMIM #309900) is 
caused by a deficit of iduronate 2-sulfatase (IDS), a key enzyme in the lysosomal 
catabolism of the mucopolysaccharides heparan- and dermatan-sulfate (Figure 
I). The clinical features of MPS II are similar to those of MPS I, ranging from the 
attenuated to the severe forms.  
Table II shows the prevalence of MPS II. 
 
1.5.1 Genetics 
The human gene coding for iduronate 2-sulfatase (IDS, EC 3.1.6.13) maps on the 
long arm of X chromosome, at location Xq28, with minus orientation. According 
to Ensembl database, it spans almost 56 kilobases and has 11 transcripts.  
A pseudogene (IDSP1, I2S2) located on the telomeric side of the IDS gene within 
20 kb has also been identified (Bondeson et al., 1995); it contains sequences 
homologous to exons 2 and 3 and to introns 2, 3, and 7 of the longest IDS 
transcript, in reverse orientation. 
To date, 534 mutations have been reported for the IDS gene 
[www.hgmd.cf.ac.uk], many of which are private (Burton and Giugliani, 2012; 
Froissart et al., 2007). They include single nucleotide substitutions, small 
deletions, insertions and indels, gross deletions, insertions and duplications, 
complex rearrangements and splicing mutations. According to a study conducted 
on 155 unrelated patients in 2007 (Froissart et al., 2007), most of them (80%) 
present with small IDS gene alterations, the others present with large gene 
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alterations. These data have been confirmed by a recent study in 103 unrelated 
South-American patients (Brusius-Facchin et al., 2014). 
MPS II is inherited as an X-linked recessive disorder; nevertheless, it has been 
well documented in a small number of females (Tuschl et al., 2005; Pina-Aguilar 
et al., 2013) in whom the most common mechanism of expression is skewed X-
chromosome inactivation of the non-mutant allele. Additional rare causes may 
include the disruption of the IDS gene through an X chromosome/autosome 
translocation or homozygosity for an IDS gene mutation (Cudry et al, 2000; 
Tuschl et al., 2005). Females carrying a mutation in one IDS allele (carriers) are 
usually asymptomatic.  
 
1.5.2 Genotype-phenotype correlation 
The high phenotypic and genotypic heterogeneity, the rarity and the presence of 
almost exclusively private mutations render genotype-phenotype correlation in 
MPS II difficult to assess. However, total or partial gene deletion and 
gene/pseudogene rearrangement seem to result in the severe phenotype 
(Froissart et al., 2002). Deletions extending beyond the IDS locus have been 
associated with a severe phenotype in combination with symptoms atypical of 
Hunter syndrome (Timms et al., 1997). Conversely, small gene alterations, such 
as single nucleotide substitutions, have been reported to be associated with a 
wide range of phenotypes, spanning the entire spectrum from severe to 
attenuate. Even the same mutation may be associated with different 
phenotypes: at least two families have been described with brothers exhibiting 
severe and attenuated forms (Martin et al., 2008). 
Neither the amount of IDS nor its activity correlates with phenotype severity in 
Hunter patients. Current methods used for measuring IDS enzymatic activity are 
insufficiently sensitive to differentiate between complete absence and presence 
of residual activity (Froissart et al., 2002). However, in vitro functional studies of 
IDS mutations reported a residual activity equal to 0.2–2.4% of the wild-type IDS 
activity for attenuated phenotypes and no detectable activity for those 
associated with severe phenotypes (Sukegawa-Hayasaka et al., 2006). Lee and 
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colleagues (Lee et al., 2012) observed a low residual IDS activity also in plasma of 
attenuated patients. 
 
1.5.3 Clinical features 
MPS II is a multiorgan and multisystem disease with variable age of onset and 
rate of progression. Phenotypic expression spans a wide spectrum of clinical 
severity. Patients with the most severe forms exhibit a chronic and progressive 
disease involving multiple organs and tissues, with increasing cognitive 
deterioration; they appear normal at birth, although they tend to be heavy. 
Clinical features manifest between 2 and 4 years of age; death from a 
combination of neurological deterioration and cardiorespiratory failure usually 
occurs in the mid-teenage years (Wraith et al., 2008; Martin et al., 2008). In 
attenuated patients, clinical signs have a later onset; they are most often 
diagnosed between the ages of 4 and 8 years. Neurologic dysfunctions are 
absent or minimal; survival to adulthood is common, but death often occurs 
between 20 and 30 years from cardiac or respiratory failure. A few patients are 
less severely affected; in these, life expectancy can be close to normal, and such 
affected males may have children. However, this traditional classification of 
patients into ‘mild’ (sometimes reported as ‘attenuated’) or ‘severe’ forms, on 
the basis of length of survival and the presence of CNS disease, is a gross 
simplification. The disorder should rather be regarded as a continuum between 
two extremes (severe and attenuated) (Wraith et al., 2008). 
Patients with MPS II exhibit hepatomegaly, associated or not with splenomegaly, 
upper respiratory tract dysfunctions with recurrent respiratory infections, 
frequent sleep apnoea and musculoskeletal disorders, such as dysostosis 
multiplex, joint stiffness, pelvic dysplasia, a typical “facies” (Figure III) and 
vertebral and rib abnormalities (Sanjurjo-Crespo, 2007; Martin et al., 2008; 
Wraith et al., 2008). Cardiologic manifestations are common and are usually 
observed around 5 years of age, generally constituting the primary cause of 
death (Martin et al., 2008). Umbilical and inguinal hernias are also frequent 
findings, as well as recurrent otitis and dental abnormalities, gingival 
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hypertrophy and hyperplasia (Sanjurjo-Crespo, 2007; Martin et al., 2008). 
Patients with MPS II also exhibit skin disorders, Mongolian spot and papular 
lesions (Martin et al., 2008; Wraith et al., 2008). 
 
 
Figure III: Photographs of an MPS II patient at the age of 6 months, 5, 9 and 30 years (from left to 
right), showing the progression of the characteristic “facies” of Hunter syndrome. 
 
From a neurological point of view, about two thirds of MPS II patients present 
with manifestations such as developmental delay and/or neurological regression 
(Schwartz et al., 2007). Patients with severe phenotype manifest an important 
neurological involvement with impaired cognitive abilities resulting in delayed 
mental developmental. In early childhood, in such patients behavioural 
problems, including hyperactivity, aggressiveness, obstinacy and stubbornness 
are common (Young et al., 1982). The attenuated form is characterized by little 
or no central nervous system involvement, with preserved intelligence and an 
extended life expectancy. In a study of magnetic resonance imaging (MRI) of 19 
patients, the prevalence of brain atrophy, hydrocephalus and white matter 
lesions are significantly higher in patients with severe cognitive involvement 
(Vedolin et al., 2007). Nevertheless, the presence of these brain lesions is not 
diagnostic of damage of cognitive skills, as white matter lesions, enlargement of 
the ventricles and obvious brain atrophy sometimes are also present in patients 
without neurological involvement (Muenzer et al., 2009). Communicating 
hydrocephalus and spinal cord compression syndrome, as well as carpal tunnel 
syndrome, may also occur (Martin et al., 2008). 
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1.5.4 Therapies 
 
1.5.4.1 Hematopoietic Stem Cells Transplantation 
Hematopoietic stem cell transplantation (HSTC) via umbilical cord blood or bone 
marrow has been proposed as a way of providing sufficient enzyme to delay or 
stop the progression of the disease (Martin et al., 2008). In MPS II the use of 
HSCT has been controversial because of the associated high risk of morbidity and 
mortality, the lack of sufficient data on long-term follow up and some negative 
results obtained in a few case reports (Vellodi, 2005; Araya et al., 2009). 
However, the results of a long-term retrospective study performed in Japan in a 
cohort of 21 HSCT-treated patients have been recently published (Tanaka et al., 
2012). HSCT showed effectiveness when performed before signs of brain atrophy 
or valvular regurgitation appear. Improvements of brain MRI, cardiac valve 
regurgitation and urinary GAG levels were observed in these patients together 
with a stabilization of brain atrophy, speech capability and activities of daily 
living. 
 
1.5.4.2 Enzyme Replacement Therapy – Elaprase® 
Idursulfase (Elaprase®, Shire Human Genetic Therapies, Inc, Cambridge, MA, 
USA) is a recombinant human IDS, produced in a human cell line, that was 
licensed for treatment of MPS II patients in the USA and the European Union, 
gaining marketing approval by the Food and Drug Administration (FDA) in 2006 
and by the European Medicines Agency (EMA) in 2007. In Italy it was approved 
by the Italian Medicines Agency (AIFA) in 2006. 
Clinical benefits of idursulfase were demonstrated in a randomized, placebo-
controlled, double-blind clinical trial (Muenzer et al. 2006), in which 96 patients 
were randomly assigned to placebo or to a 0.5 mg/kg idursulfase dosage that 
was infused either weekly or every other week (EOW). After 1 year of treatment, 
a statistically significant improvement rate of the primary end point, compared 
with placebo, resulted both in patients in which the idursulfase was infused 
weekly and in the EOW group, even if in the weekly group it was more 
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significant. A significant reduction of GAG excretion and liver and spleen volumes 
was observed. On the basis of the larger clinical response in the weekly group 
compared with the EOW group, idursulfase was approved for the treatment of 
MPS II in both the USA and European Union at a dose of 0.5 mg/kg weekly. 
Other clinical trials of idursulfase have been conducted in patients with MPS II. A 
recent study in 27 Italian paediatric patients revealed a statistically significant 
reduction only of urinary GAG and hepatomegaly. The evaluation of ERT efficacy 
in relation to the severity of the disease evidenced slightly higher improvements 
as for hepatomegaly, splenomegaly, otological disorders and adenotonsillar 
hypertrophy in severe vs attenuated patients (Tomanin et al., 2014). 
 
1.5.4.3 Other therapies 
Several new approaches for the treatment of MPS disorders are under 
investigation; some of these could be stand-alone therapies, others would likely 
be used as adjuvant therapy. Among these, both viral and non-viral approaches 
have been tested for the treatment of Hunter syndrome. Even if only in 
preclinical animal experiments, the obtained results have been encouraging. 
Gene therapy mediated by adeno-associated vectors (Cardone et al., 2006; Jung 
et al., 2010) obtained good results as well as cell therapy approaches employing 
intraperitoneally implanted microcapsules (Friso et al., 2005). Also muscle 
electro gene transfer has been tested, obtaining an elevated production of 
therapeutic protein but little curative effects in organs far from the injection site 
(Friso et al., 2008). 
A therapeutic approach of substrate reduction therapy for Hunter syndrome 
uses genistein. It could be useful in combined therapeutic protocols and has 
shown efficacy in MPS II mice (Friso et al., 2010). Being a diet supplement, 
genistein can be assumed with no prescription, therefore in the last few years 
numerous MPS patients have regularly taken it, despite no important clinical 
trials evaluating both efficacy and safety have been so far carried on. 
In 2012, Calias and colleagues demonstrated that IT-lumbar administration of IDS 
results in the delivery of a significant fraction of the administered protein to the 
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brain with widespread deposition in monkeys, dogs and mice, thus suggesting a 
clinically feasible route for the delivery of IDS to the brain (Calias et al., 2012). 
Recently it was also demonstrated that repeated intraventricular infusion 
(Higuchi et al., 2012) and continuous intrathecal infusion (Sohn et al., 2013) of 
IDS was effective in improving CNS defects in the MPS II mice and could be a 
valuable therapeutic method for treating patients. 
 
1.6 MPS I AND MPS II MOUSE MODELS 
 
1.6.1 MPS I mouse model 
The first mouse model for MPS I was created in 1997 by Clarke and collaborators 
by homologous recombination in embryonic stem cells (ES cells). 
The clinical and pathological characterization of the knock-out mouse is similar 
to the severe form of human MPS I, with evident dysmorphism of the muzzle, 
thickening of the cheek bones and long bones, enlargement of the fingers and 
increased urinary GAG excretion. Brain analysis also revealed an altered 
concentration of secondary factors such as ganglioside GM3, GM2 and GD3 
(Clarke et al., 1997). 
About 10 years ago Elizabeth Neufeld described the generation of a second 
knock-out mouse for MPS I, obtained with the same mechanism of specific site-
recombination of the Neo cassette within exon 6 described by Clarke. This 
mouse model is similar, but not identical to the previous one (Ohmi et al., 2003). 
Besides the dimorphism of the muzzle and the thickening of the fingers, it also 
displays cardiac hypertrophy with significant interventricular septal thickening 
due to infiltration of cells filled with GAG and defects to the valves and the aortic 
arches, reflecting the cardiomyopathy aspects observed in patients with MPS I 
(Jordan et al., 2005). 
Knockout mice of the latter model were kindly provided us by Jean Michel Heard 
(Pasteur Institute, Paris) and have been used in the experiments described in this 
thesis. 
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1.6.2 MPS II mouse model 
The Ids knock-out (Ids-ko) mouse was generated by gene disruption: a portion of 
exon 4 and all of exon 5 (a 1.5 kb deletion) were replaced by a neomycin-
resistance gene expression cassette, in a C57BL/6 strain background (Muenzer et 
al., 2002). The Ids-ko mouse was characterized by several groups (Muenzer et al., 
2002; Friso et al., 2005; Cardone et al., 2006; Garcia et al., 2007). The animal 
shows many of the metabolic and skeletal abnormalities characterizing the 
human disease, therefore representing a good model for MPS II. Our analysis 
detected hepatosplenomegaly, sometimes accompanied by cardiomegaly, and 
extremely high tissue GAG deposits. Significantly elevated urinary GAG levels can 
be measured in the model starting at 6-8 weeks of age, increasing with time, 
thus rendering the evaluation of urinary GAG level a useful indicator of 
pathology as well as of treatment efficacy. No plasmatic and tissue enzymatic 
activity is detected. The neurological involvement was first assessed by Cardone 
and colleagues (Cardone et al., 2006); brain GAG accumulation is mainly 
detected within the choroids plexus of the ventricular region (Cardone et al., 
2006; Friso et al., 2010). 
 
1.7 BLOOD-BRAIN BARRIER AND DRUG TRANSPORT 
 
1.7.1 The blood-brain barrier 
Each neuron is perfused by its blood vessel; it is estimated that in the human 
brain there are about 100 billion capillaries for a total of 600 km in length. This 
dense vascular network covers an area of about 20 square meters and is 
therefore the most important interface between the blood and the brain in 
terms of trade of gas and metabolites essential to support brain function (Nag et 
al., 2005). 
The blood-brain barrier (BBB) is a real barrier between the bloodstream and the 
central nervous system (CNS), acting as a "selective biological filter", allowing or 
preventing the passage of substances (ions, glucose, protein, etc.) from the 
blood into the brain parenchyma and into the cerebrospinal fluid (CSF). Thanks 
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to this regulatory and selective function, BBB preserves the delicate chemical-
physical homeostasis of the cerebral fluid environment. Therefore, BBB plays a 
protective role towards the CSF and the nervous tissue. Indeed, the BBB 
maintains the stable ionic environment and preserves the low aminoacidic 
gradient of the excitatory neurotransmitter (glutamic acid, aspartic acid and 
glycine), characteristic of the cerebral extracellular fluid. This is essential for a 
reliable synaptic transmission and an efficient neuroregulation activity. It also 
prevents the entry of toxic substances for cells, such metabolites and 
neurotoxins both endogenous and xenobiotic, potentially even fatal. In so doing, 
it promotes CNS longevity and prevents premature cell death and 
neurodegeneration (Begley, 2004). 
The BBB consists of endothelium of brain capillaries, perivascular astrocyte 
processes surrounding the endothelial cells and pericytes, contractile connective 
cells that partially surround endothelial cells. The characteristic anatomical 
constitution of BBB is responsible for its functional peculiarities, such as limited 
permeability to most of the substances and the limited paracellular and trans-
cellular transport. The brain capillaries are anatomically different from  systemic 
peripheral capillaries, as the cells that compose them form a continuous 
endothelium, not fenestrated, and with a reduced number of pinocytotic cells. 
Moreover, there are tight junctions that prevent the free diffusion of solutes 
from the blood compartment (peripheral or systemic) to the CSF and brain 
(intrathecal), both at the level of the brain capillaries and choroid epithelium 
(Abbott et al., 2010). 
Astrocytes and pericytes, located around endothelial cells, being in turn 
separated from the basal membrane by an extracellular matrix of collagen, help 
to ensure further compactness to this anatomical and functional unit (Abbott et 
al., 2010). 
Therefore, to convey a drug to the brain is necessary to consider the structural 
and functional characteristics of the BBB and evaluate the chemical and physical 
properties (pKa, molecular weight, lipophilicity, etc.) of the drug. We must also 
consider its intrinsic ability to form bonds with the plasma proteins that prevent 
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the passage to the CNS; the degree of ionization (pH) (ionized drugs do not 
penetrate into the CNS) and the lipid/water partition coefficient. Drugs with a 
high partition coefficient, ie fat-soluble and with a molecular weight below 400-
500 Da, are able to cross the membranes and penetrate into the CNS by simple 
passive diffusion; those with low partition coefficient can penetrate the CNS only 
by carrier-mediated transport (Scarpa et al., 2012). 
It has been estimated that about 98% of the drugs for the treatment of cerebral 
pathologies cannot effectively overcome the BBB due to the lack of a specific 
mechanism of passage, or because of their high molecular weight or polarity 
(Pardridge, 2005). 
 
1.7.2 Transport across the BBB 
Oxygen, carbon dioxide, glucose, nucleosides, vitamins, and part of the fat-
soluble drugs are able to cross the BBB due to mechanisms of passive diffusion 
(lipophilic substances) or through specific transport mechanisms (Abbott et al., 
1996; Begley et al., 2008).The endogenous transport systems may be present on 
the luminal or abluminal side of the BBB and can be classified into three 
categories: 1) CMT Carrier-Mediated Transport (CMT); 2) Active Efflux Transport 
(AET); 3) Receptor-Mediated Transport (RMT). CMT and AET systems are 
responsible for the transport of small molecules between blood and brain, while 
the RMT systems allow the transport of larger molecules across the BBB. Among 
these the ATP Binding Cassette, the Organic Anion Transporting-Polypeptide and 
the Organic Anion Transporter play an important role.  
In addition to the possibility to exploit or inhibit these and other transport 
mechanisms physiologically present on the BBB (Pardridge, 2003), other 
approaches, that can ensure a more effective channelling of drugs to the CNS, 
are being investigated.  The approaches to achieve effective concentrations of 
drugs into the CNS may be invasive (temporary rupture of tight junctions, 
intracerebral injection or use of intracerebral implants such as catheters, 
microchip or erodible polymer systems). These approaches are still difficult to 
apply, expensive and potentially dangerous for patients, since the direct delivery 
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of the drug exposes patients to the risk of developing serious brain infections, 
resulting in significant decrease in their compliance. Therefore, the research is 
primarily aimed at developing non invasive approaches (chemical, biological or 
technological) (Scherrmann, 2002). 
 
1.7.3 Nanotechnologies and BBB 
Today knowledge in pharmaceutical nanotechnology combined with expertise in 
biomedical sciences represents an important promise for the distribution of 
drugs across the BBB (Kreuter, 2013). Nanomedicine, which involves the use of 
nanoparticles or nanostructures, is a rapidly evolving field with great 
expectations, given the ability of multifunctional nanoparticles to cross the BBB. 
Maybe the most difficult task will be to design and develop nanoparticles that 
can specifically target a subset of neurons without affecting other neuronal 
populations. Underlying this approach is the design and testing of micro/nano 
particles, micro/nano capsules, lipoproteins, liposomes and micelles for the 
transport and release of the drug into the CNS. 
Various types of vesicular structures or matrix have been defined, in which the 
drug is localized into the cavity enclosed by the polymeric membrane or is 
physically and uniformly dispersed in a polymer matrix. In addition to these 
traditional systems other more innovative ways, such as the use of dendrimers, 
nanogels, nanoemulsions and nanosuspensions (Begley et al., 2008; Wong et al., 
2012; Wagner et al., 2012) are also being tested. All these materials are carefully 
formulated, so as to be biodegradable, biocompatible, non-toxic and non-
immunogenic. They allow a release of the drug according to predetermined 
kinetics. Polymeric nanoparticles, whose size generally vary between 100-400 
nm, constitute one of the most promising approaches, since their polymeric 
structure makes them more stable in biological fluids, ensuring protection of the 
drug from degradation of the biological environment compared to phospholipid 
bilayer of vesicles or liposomes. They are generally constituted by biocompatible 
and biodegradable materials, such as butyl cyanoacrylate (PBCA), human serum 
albumin (HSA), and lactic-co-glycolic acid (PLGA). Thanks to their small size they 
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can transport drugs across the BBB by endocytosis, by the endothelial cells lining 
the blood vessels of the brain and probably also by transcytosis of the 
nanoparticles themselves. Given the promising perspectives, new types of 
nanoparticles have been developed, obtained from polymers modified with 
appropriate peptidic ligands, which improve the biocompatibility and increase 
the selectivity. This solution is able to ensure high specificity in terms of BBB 
crossing for efficient drug delivery to the CNS, useful in the treatment of 
neurodegenerative brain diseases, tumours, ischemia and cerebral infections 
difficult to treat (Costantino et al., 2005). Not only, it also results in a beneficial 
reduction of the therapeutic dose, resulting in a decrease of the collateral 
damage of the drugs; the addition of these peptidic ligands promotes direct 
interaction with the transport systems to the CNS (Grabrucker et al., 2011; Tosi 
et al., 2011a).  
This approach probably represents the future for treatment of LSDs and not only. 
The ability to assemble molecules with high and low molecular weight, siRNA, 
etc. inside molecules that are conveyed through the BBB, without altering it, 
surely will have an applicative development also for more common 
neurodegenerative, such as Parkinson's disease, Alzheimer's disease, etc. 
Currently, preclinical studies have not shown particular adverse events following 
intravenous or repeated localized administrations; moreover, the use of peptides 
binding receptors on different organs enable the correction of other districts, as 
well as the neurological compartment (Scarpa et al., 2012). 
Since nanoparticles are now proposed in oncology (Jabir et al., 2012), with 
significant results in the control of some forms of cancer, further studies are 
needed to verify the absence of possible side effects resulting from chronic 
administration, given that substances used in production may induce 
immunological reactions (Syed et al., 2013). 
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1.8 PLGA-NANOPARTICLES FOR CNS THERAPY 
Polymeric nanoparticles (NPs) showed to be promising carriers for CNS drug 
delivery, due to their potential both in encapsulating drugs, hence protecting 
them from the body excretion and metabolism, and in delivering active agents 
across the BBB without inflicting any damages to the barrier itself (Kabanov et 
al., 2007; Tosi et al., 2008). Different polymers have been tested and different 
strategies have been applied; among these, mainly the use of poly-lactide-co-
glycolide (PLGA), an FDA-approved polymer, and of specific ligands, able to 
render the delivery of drugs to CNS more targeted, has been recently considered 
(Costantino et al., 2009; Ruozi et al., 2014a; Tosi et al., 2014a; Vilella et al., 2014; 
Tosi et al., 2013a; Tosi et al., 2013b; Tosi et al., 2013c). In particular, it was 
shown that the PLGA-NPs derivatized with the peptide H2N-Gly-L-Phe-D-Thr-Gly-
L-Phe-L-Leu-L-Ser(O-β-D-Glucose)-CONH2 [g7] are able to cross the BBB (Tosi et 
al., 2007).  
Several experiments were performed, starting with an electron microscopy study 
and the recognition of g7-NPs at the BBB level after intravenous administration 
in rats and computational analysis on glycopeptides covering NPs. The results 
highlighted an interaction between g7-NPs and the BBB and 
endocytosis/macropinocytosis pathways for BBB crossing (Tosi et al., 2011b; 
Sahay et al., 2010). 
The same results were also highlighted in vitro on neurons/glial cell cultures 
(Grabrucker et al., 2011), evidencing the endocytotic pathways as g7-NPs cell 
entrance as well as assessing the safety of g7-NPs since they do not create any 
damage to cells, even at high doses. Other previous in vivo biodistribution and 
pharmacological proof-of-evidence studies of brain delivery of model drugs (not 
able to reach the brain alone, such as rhodamine-123 and loperamide) 
demonstrated the ability of g7-NPs to create BBB interaction and trigger an 
efficacious BBB crossing (Tosi et al., 2007, 2008, 2010, 2011b), up to 10–15% of 
the injected dose (Vergoni et al., 2009). 
The fate of g7-NPs inside the CNS, once crossed the BBB, was investigated in 
neuronal cells and in mice, elucidating the uptake pathways in neurons both in 
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vitro and in vivo. In particular, clathrin and Rab-5 pathways were identified as 
responsible for NPs uptake and trafficking into neuronal cells. Interestingly, 
following intracellular passage, g7-NPs were found to be transferred, in different 
percentages, from cell to cell by tunneling nanotubes, released outside the cells 
or accumulate in lysosome vesicles. This last finding, considered a drawback for 
drug delivery to neurons cytoplasm, as recently reported (Chhabra et al., 2014), 
in the case of LSDs can, on the opposite, be considered an advantage since 
lysosomes, site of NPs accumulation, are themselves targets for LSDs therapy.  
At present, some clinical trials have proposed the use of PLGA-NPs as drug 
carriers, but none has so far evaluated their use for the treatment of CNS 
diseases. In the context of LSDs, the set-up of a therapeutic protocol addressing 
the neurological deficit would dramatically improve patients’ conditions. 
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2. AIMS 
 
Lysosomal Storage Disorders (LSDs) are a group of neurometabolic syndromes, 
mostly due to the deficit of one lysosomal enzyme. Many LSDs affect most of the 
organ systems and about two-thirds of the patients present neurological and 
cognitive impairment.  
Enzyme replacement therapy (ERT), the most common therapeutic strategy 
applied to some LSDs, although determining some clinical improvements, has 
revealed to be ineffective on the CNS disease, due to enzymes' inability to cross 
the blood-brain barrier (BBB). 
Among LSDs, Mucopolysaccharidosis type I (MPS I, Hurler syndrome) and Type II 
(MPS II, Hunter syndrome) are both characterized by a lack of activity of 
lysosomal enzymes involved in the catabolism of the glycosaminoglycans eparan- 
and dermatan-sulfate, therefore accumulated in the cell compartment and in the 
extracellular matrix. While presenting different forms of clinical severity and 
different degrees of progression, both diseases affect most organs and systems 
and about 2/3 of the patients have an important cognitive and neurological 
involvement. 
ERT, applied to both diseases in recent years, has shown some clinical 
improvement, but also some limitations: among these the inability to transport 
acid hydrolases across the BBB, due to the high molecular weight, which makes 
any paracellular or transcellular diffusion of these proteins practically not-
existent. Therefore, it is necessary to evaluate alternative methods to reach the 
CNS. 
With this aim, we evaluated the ability of polymeric nanoparticles (PLGA-NPs), 
modified with a glycopeptide of 7 amino acids (g7), already tested for molecules 
of low molecular weight, to bypass the BBB and deliver the therapeutic 
recombinant enzymes to the CNS after systemic administration in the mouse 
models for the two diseases, ensuring a prolonged drug release and protection 
from inactivation. 
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Before conducting a functional and efficacy study, we performed several 
preliminary experiments to explore the ability of the g7-PLGA-NPs (g7-NPs) to 
transfer through the BBB of the MPS I and MPS II mouse models a model drug 
(FITC-albumin) with a high molecular weight, comparable to that of the 
recombinant enzymes used for ERT. 
Thereafter, we evaluated in vitro the ability of untargeted PLGA-NPs (devoid of 
g7), loaded with the recombinant enzyme for MPS II (u-NPs-IDS), to maintain the 
therapeutic activity of the drug. 
Finally, we tested in vivo, in the MPS II mouse model, efficiency and efficacy of 
the g7-NPs loaded with the recombinant enzyme (g7-NPs-IDS). 
Evaluation of safe delivery systems able to transport therapeutic drugs across 
the blood-brain barrier, in addition to allow efficacy studies for neuronal LSDs, 
may also provide new hope for the treatment of other neurometabolic disorders 
as well as chronic neurodegenerative diseases. 
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3. MATERIALS AND METHODS 
 
3.1 MOUSE MODELS 
The C57BL/6 Idua knockout (Idua-ko) mouse, providing the model for MPS I, 
generated in the laboratory of Dr. Neufeld (David Geffen School of Medicine, 
UCLA, USA), was kindly provided by Dr. Heard (Pasteur Institute, Paris, France); 
the mouse was generated by targeted gene disruption of the murine Idua gene 
and previously characterized (Ohmi et al., 2003). 
The C57BL/6 Ids knockout (Ids-ko) mouse, providing the model for MPS II, was a 
kind gift of Dr. Muenzer (University of North Carolina, NC, USA) and was 
generated by gene disruption of the murine Ids gene and previously 
characterized (Muenzer et al., 2002; Friso et al., 2005; Cardone et al., 2006; 
Garcia et al., 2007).  
Both colonies were expanded in our animal facility and mice were genotyped by 
multiplex PCR. In the experiments here described Idua-ko, Ids-ko and wild-type 
(wt) mice were housed in light and temperature controlled conditions, with food 
and water provided ad libitum. All animal care and experimental procedures 
were conducted according to the current national and international animal 
ethics guidelines. 
 
3.2 NANOPARTICLES 
All different batches of nanoparticles were prepared and analysed by the 
Te.Far.TI group (Department of Life Sciences, University of Modena and Reggio 
Emilia) in the figure of Dr. Giovanni Tosi and his laboratory. 
All the nanoparticles (NPs) used in this study were prepared by the technique of 
water/oil/water (W/O/W) double emulsion, which, as reported in literature, is 
the most suitable for the encapsulation of hydrophilic molecules (Jain RA, 2000). 
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3.2.1 Chemicals 
Poly(D,L-lactide-co-glycolide) (PLGA, RG503H, MW near 11,000) was used as 
received from the manufacturer (Boehringer-Ingelheim, Ingelheim am Rhein, 
Germany). Polyvinyl alcohol (PVA, MW 15,000) was purchased from Sigma-
Aldrich (Milan, Italy). Gly-L-Phe-D-Thr-Gly-L-Phe-L-Leu-L-Ser(O-β-D-Glucose)-
CONH2 (g7) linked to biotin was synthetized as previously reported (Tosi et al., 
2014) and purchased from Mimotopes (Clayton, Victoria, Australia). PLGA 
conjugated with Rhodamine B piperazine amide (Sigma-Aldrich) (R-PLGA) was 
prepared as previously described (Bondioli et al., 2010; Tosi et al., 2011a). 
Trehalose dihydrate (MW 378.33) was purchased by Sigma-Aldrich and used as  
cryoprotectant. Maleimide activated Neutravidin (NA-Maleido) was obtained by 
Thermo Scientific. A MilliQ water system (Millipore, Bedford, MA, USA), supplied 
with distilled water, provided high-purity water (18 MΩ). All the other chemicals 
were of analytical grade. 
 
3.2.2 NPs/Alb preparation 
Nanoparticles (NPs) were prepared by a double emulsion technique (Rosca et al., 
2004; Ruozi et al., 2014b). Briefly, 1 ml of FITC-albumin water solution (20mg/ml) 
was emulsified in 5 ml CH2Cl2 solution of polymer (95 mg of PLGA and 5 mg of R-
PLGA) under cooling (5°C) by using a probe sonicator (Microson Ultrasonic cell 
disruptor, Misonix Inc. Farmingdale, NY, USA) at 80W for 45 sec to obtain a w/o 
emulsion (first inner emulsion). The first inner emulsion was rapidly added to 12 
ml of 1% (w:v) PVA aqueous solution and the w/o/w emulsion was formed under 
sonication (80W for 45 sec) at 5°C. Formulation was mechanically stirred (1,500 
rpm) for at least 1h (RW20DZM, Janke&Kunkel, IKA-Labortechnik, Staufen, 
Germany) at RT until the complete solvent evaporation and finally purified by Hi-
Speed Refrigerated Centrifugation (Beckman J21) at 17000 rpm for 10 min at 5°C, 
washed several times with water and re-suspended in water. This technique 
allowed to obtain labelled Alb-loaded un-modified NPs (u-NPs/Alb), used as 
controls. As control samples, un-loaded NPs were obtained by substituting the 
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FITC-albumin solution with saline solution, leading to un-targeted un-loaded NPs 
(u-NPs). 
In order to obtain brain targeted NPs (un-loaded g7-NPs or loaded g7-NPs/Alb) 
g7 was conjugated on the surface of NPs using a post-modification approach 
(Nobs et al., 2004). 
Briefly, 50 mg of each preparation was suspended in 2-(N-morpholino) 
ethanesulfonic acid (MES, Sigma Aldrich) buffer and reacted with 50 mg of N-
Hydroxy-succinimide (NHS, Sigma Aldrich) and 150 mg of 1-Ethyl-3-(3-
dimethylaminopropyl)-carbodiimide (EDC; Sigma Aldrich, Saint Luis, MO) to 
activate carboxylic group of the polymer. After 1 hour, activated NPs were 
collected by ultracentrifugation at 17000 rpm for 10 min at 4°C and the excess of 
reagents was removed. NPs were re-suspended in PBS pH 7.4 and reacted with 2 
mg NA-Maleido, previously activated by adding 20 µl of cysteamine (2mg/ml). 
Mixture was mechanically stirred for 2 hours at RT and the neutravidin modified 
NPs (NA-NPs) were purified by Hi-Speed Refrigerated Centrifugation (Beckman 
J21) at 17000 rpm for 10 min at 5°C. Finally, biotinylated g7 peptide (2.6 mg) was 
solubilized in 1 ml of water and reacted with NA-NPs for 1 hour at room 
temperature. G7 modified nanoparticles were than purified by centrifugation as 
previously described for un-targeted NPs. 
All the NP formulations were frozen using trehalose as cryoprotectant (1:1 w:w 
polymer/trehalose ratio) and stored at -20°C. 
Other control samples included a mixture of un-loaded targeted NPs (g7-NPs) 
suspended in FITC-albumin solution (MIX1), un-loaded un-targeted NPs (u-NPs) 
suspended in FITC-albumin solution (MIX2). 
 
3.2.3 NPs-IDS preparation 
2.5 ml of Elaprase® (corresponding to 5 mg of IDS enzyme) were lyophilized and 
then resuspended in 500 µl of deionized water to obtain an enzyme solution with 
a concentration of about 10 mg/ml. This solution was emulsified in 2.5 ml CH2Cl2 
solution of polymer (45 mg PLGA +  5 mg g7-PLGA for g7-NPs-IDS, or 42.5 mg 
PLGA + 5 mg g7-PLGA + 2.5mg R-PLGA) under cooling (5°C) by using a probe 
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sonicator (Microson Ultrasonic cell disruptor, Misonix Inc. Farmingdale, NY, USA) 
at 80W for 45 sec to obtain a w/o emulsion (first inner emulsion). The first inner 
emulsion was rapidly added to 8 ml of 1% (w:v) PVA aqueous solution and the 
w/o/w emulsion was formed under sonication (80W for 45 sec) at 5°C. 
Formulation was mechanically stirred (1,500 rpm) for at least 1h (RW20DZM, 
Janke&Kunkel, IKA-Labortechnik, Staufen, Germany) at RT until the complete 
solvent evaporation and finally purified by Hi-Speed Refrigerated Centrifugation 
(Beckman J21) at 17000 rpm for 10 min at 5°C, washed several times with water 
and re-suspended in water. 
All the NP formulations were frozen using trehalose as cryoprotectant (1:1 w:w 
polymer/trehalose ratio) and stored at -20°C. 
 
3.2.4 NPs characterization 
 
3.2.4.1 Chemico-physical characterization 
All the batches of NPs were characterized regarding their surface, chemico-
physical and morphological properties. In particular, for surface properties (size 
and charge), NPs in distilled water were analyzed by photon correlation 
spectroscopy (PCS) and laser Doppler anemometry using a Zetasizer Nano ZS 
(Malvern, UK; Laser 4 mW He–Ne, 633 nm, Laser attenuator Automatic, 
transmission 100% to 0.0003%, Detector Avalanche photodiode, Q.E. > 50% at 
633 nm, T = 25°C). The results were normalized with respect to a polystyrene 
standard solution. 
To evaluate shape and morphology of NPs, a scanning electron microscope (SEM) 
(XL-40; Philips, Eindhoven, The Netherlands) operating at 8 kV was used. NPs 
were re-suspended in distilled water after at least 3 washings with water, and a 
drop of the suspension was placed onto a SEM sample holder and dried under 
vacuum (10–2 mmHg). The dried samples were coated under argon atmosphere 
with a 10 nm gold palladium thickness (Emitech K550 Super Coated; Emitech Ltd, 
Ashford, Kent, UK) to increase electrical conductivity. The NPs were then 
3. Materials and Methods 
 37 
processed for the evaluation of their morphology and shape by analyzing images 
at different magnifications (13,000× to 16,000×). 
Moreover, Atomic Force Microscopy (AFM) was used for morphological 
assessments. In particular, AFM was used (Park Instruments, Sunnyvale, CA, USA) 
at RT (about 20°C), at atmospheric pressure (760 mmHg) operating in air and in 
non-contact mode, using a commercial silicon tip-cantilever (tip diameter ≈5-10 
nm) with stiffness about 40 Nm-1 and a resonance frequency around 150 kHz. A 
little amount of each NP sample was dispersed in deionised water (about 40 μL) 
on a small freshly cleaved mica disk (1 cm x 1 cm). After 2 min from the 
deposition, the excess of deionised water was removed by a blotting paper and 
the sample observed. Two kinds of images were obtained: the first one is a 
topographical image and the second one is the 3D elaboration. The AFM images 
were obtained with a scan rate of 1 Hz and processed using a ProScan Data 
Acquisition software developed under Windows 95. 
 
3.2.4.2 Albumin and IDS content 
Freeze-dried NPs (5 mg) were dissolved in 1 ml of DCM. Then, 3 ml of PBS, pH 7.4 
were added to extract the FITC-albumin or IDS and the organic solvent was 
evaporated at RT under stirring (1,500 rpm for at least 1h; RW20DZM, 
Janke&Kunkel, IKA-Labortechnik, Staufen, Germany). The aqueous solution was 
filtered (cellulose acetate filter, porosity 0.2 µm, Sartorius) to remove the 
polymer residues and spectrophotometrically analysed at 492 nm to evaluate the 
FITC-albumin or IDS concentration. The drug loading was expressed as mg of 
FITC-albumin or IDS encapsulated/100 mg of NPs and as encapsulation efficiency 
(EE%), i.e. the percentage of encapsulated drug related to the initial amount of 
drug used in the preparation. 
 
3.2.4.3 ESCA analysis 
The presence of g7 on NPs surface was demonstrated by electron spectroscopy 
for chemical analysis (ESCA), showing the presence of nitrogen atoms on the 
surface of antibody-engineered NPs, as previously described (Liu et al., 2010). 
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ESCA was performed on a XRC 1000 X-ray source analysis system (Specs Surface 
Nano Analysis, Germany) and a Phoibos 150 hemispherical electron analyzer 
(Specs Surface Nano Analysis, Germany), using MgKα1,2 radiations. Spectra were 
recorded in fixed retardation ratio (FAT) mode with 40 eV pass energy. The 
pressure in the sample analysis chamber was around 10−9 mbar. Data were 
acquired and processed using the SpecsLab2 software. 
 
3.3 IN VIVO PRELMINARY STUDY OF g7-NPs IN MPS I AND MPS II 
MOUSE MODELS  
The preliminary study was conducted to evaluate the ability of the g7-PLGA-NPs 
(g7-NPs) to transport high molecular weight molecules to the CNS. Albumin was 
used as a model drug. 
Idua-ko, Ids-ko and matched wt mice (5-8 months old) were intravenously (iv) 
injected as indicated in Table IV. For each batch of PLGA-NPs, 2 mg were 
intravenously injected in each mouse; as for albumin, 0.2 mg/animal were 
injected, both free and NPs-loaded. 
3-5 animals were sacrificed 2h post-injection by cervical dislocation for all type of 
treatment. Mice tissues (brain and liver) were collected and fixed in 4% 
paraformaldehyde and 0.2% picric acid in 1X PBS for 48h. Then, tissues were 
subjected to a sucrose gradient: 15% sucrose in PBS for 24h and then 30% 
sucrose in PBS for additional 24h. Finally, tissues were embedded in Tissue-Tek® 
O.C.T™ Compound (Sakura) and snap-frozen using dry ice. Before freezing, brains 
were cut at bregma level. Serial 5 μm thick cryosections, from the bregma to the 
cerebellum, were obtained, washed 3 times in cold PBS, mounted with 
Fluoromount™ (Sigma-Aldrich) with DAPI (BioChemica, AppliChem) and stored at 
+4°C until confocal analysis. 
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MOUSE MODEL TYPE OF INJECTION 
Idua-ko/wt 
 
g7-NPs 
u-NPs 
Alb 
g7-NPs/Alb 
u-NPs/Alb 
MIX1 (g7-NPs+Alb) 
MIX2 (u-NPs+Alb) 
EB 
Ids-ko/wt 
Alb 
g7-NPs/Alb 
EB 
 
Table IV: g7-NPs = un-loaded and targeted NPs; u-NPs = un-loaded and un-targeted NPs; Alb = 
Albumin; g7-NPs/Alb = targeted NPs loaded with albumin; u-NPs/Alb = un-targeted NPs loaded 
with albumin; MIX1 (g7-NPs+Alb) = un-loaded targeted NPs suspended in FITC-albumin solution; 
MIX2 (u-NPs+Alb) = un-loaded and un-targeted NPs suspended in FITC-albumin solution; EB = 2% 
Evans blue solution. n=3-5 for all type of injection and for both mouse model (Idua-ko and 
syngeneic wt; Ids-ko and syngeneic wt). 
 
3.4 CHECKING BBB INTEGRITY 
To check BBB integrity and exclude possible damages, we used Evans blue (EB) 
fluorescent dye (MW: 960.8, Sigma-Aldrich), as a tracer. Since serum albumin 
cannot cross the barrier, and virtually all EB is bound to albumin, if BBB is intact, 
the neural tissue remains unstained (Kozler and Pokorný, 2003); instead, when 
BBB is compromised, the albumin-bound EB enters the CNS. In this study 50 μl of 
a 2% solution EB in 0.9% NaCl was iv-injected in Idua-ko, Ids-ko and respective wt 
mice. Four hours later mice were sacrificed by cervical dislocation and the brains 
collected and processed as described in section 3.3. 
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3.5 IN VIVO PRELMINARY STUDY OF g7-NPs-IDS-R IN THE MPS II 
MOUSE MODELS 
To confirm that g7-NPs can transport IDS through the BBB, a preliminary study 
was conducted using g7-NPs loaded with recombinant IDS (Elaprase®, Shire 
Human Genetic Therapies, Inc, Cambridge, MA, USA) and marked with 
Rhodamine (g7-NPs-IDS-R).  
6 Ids-ko and 6 wt mice were iv-injected with g7-NPs-IDS-R (corresponding to 0.5 
mg/kg of IDS) and sacrificed after 2h. Livers and brains of 3 Ids-ko and 3 wt mice 
were fixed in 4% paraformaldehyde and 0.2% picric acid in 1X PBS for 48h; then 
they were processed as described in section 3.3. 
Brains of 3 Ids-ko and 3 wt mice were separated in the capillary and parenchymal 
fractions and the last one analyzed for IDS activity (see section 3.9 for both 
protocol details). 
 
3.6 IN VITRO ANALYSIS OF u-NPs-IDS EFFICACY 
To verify NPs capability to encapsulate the recombinant enzyme and transport it 
to the cells maintaining its therapeutic efficacy, an in vitro study was conducted 
on primary fibroblasts obtained from MPS II and healthy control patients. 
Human fibroblasts from skin biopsy of 3 MPS II pediatric patients, carrying 
different mutation in IDS gene, were obtained from “Cell Line and DNA Bank 
from Patients Affected by Genetic Diseases”, Gaslini Institute (Genoa, Italy). As 
healthy controls, human fibroblasts from 3 children circumcisions were used; 
they were obtained from the Histology Unit of the Department of Histology, 
Microbiology and Medical Biotechnology (University of Padua, Padua, Italy). 
Written informed consents were obtained from patients at the time of biopsy. 
All cells were anonymously obtained. 
Primary fibroblasts were cultured at 37°C in 5% CO2 atmosphere in RPMI 
medium supplemented with 15% fetal bovine serum (FBS), 100 U/ml penicillin 
and 100 ng/ml streptomycin (all Life Technologies, Milan, Italy). 
Cells were either treated with 15 mM free IDS or with IDS encapsulated in NPs 
(u-NPs-IDS) or untreated. Fibroblasts were treated for 7 days, then the treatment 
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was removed and cells sacrificed after 0, 7 and 14 days. Cell pellet was washed 
with 0.9% NaCl and then re-suspended in the same solution, sonicated and 
analyzed for induced IDS activity and GAG content (see section 3.9 for protocol 
details). 
 
3.7 IN VIVO PILOT STUDY IN THE MPS II MOUSE MODEL 
To evaluate transfer efficiency and the enzymatic activity induced by g7-NPs 
loaded with the recombinant enzyme (g7-NPs-IDS), we conducted an in vivo pilot 
study in the MPS II mouse model. 
Mice were treated with a single dose of free IDS, g7-NPs-IDS, u-NPS-IDS (all 
corresponding to 1mg/kg of IDS) or untreated. Plasma was collected by 
submandibular sampling after 4h, 24h, 7 and 14 days; then, it was analyzed for 
induced IDS activity (see section 3.9 for protocol details). 
After 7 or 14 days, 3 animals per treatment were sacrificed by cervical 
dislocation; organs (liver, kidney, spleen, heart) were collected and livers 
analyzed for induced IDS activity; brains were separated in the capillary and 
parenchymal fractions and the last one analyzed for IDS activity (see section 3.9 
for protocol details). 
 
3.8 IN VIVO MEDIUM-TERM EFFICACY STUDY IN THE MPS II MOUSE 
MODEL 
To assess the efficacy of g7-NPs-IDS, an in vivo study was conducted in the MPS II 
mouse model. 8 mice were treated once a week with g7-NPs-IDS (corresponding 
to 1 mg/kg of IDS) for 6 weeks. As control, 8 Ids-ko mice treated with free IDS, 8 
untreated Ids-ko mice and 8 wt were also analyzed. 
Before starting treatment (pre), after 3 weeks and after 6 weeks of treatment 
plasma was collected by submandibular sampling; urine was also collected using 
metabolic cages for 24 hours. Plasma was analyzed for induced IDS activity and 
urine for GAG content (see section 3.9 for protocol details). 
Mice were sacrificed by cervical dislocation after 6 weeks of treatment. Organs 
(liver, kidney, spleen, heart) of 5 mice per treatment (Ids-ko with g7-NPs-IDS, Ids-
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ko with free IDS, untreated Ids-ko and wt) were collected and livers analyzed for 
induced enzyme activity and GAG content. Brains were separated in the capillary 
and parenchymal fractions and the second one subjected to the same analysis of 
livers. 
The organs (brain, liver, kidneys, spleen, heart) of 3 mice per treatment were 
collected, and fixed in Bouin's solution. Brains and livers were analyzed by 
histological staining with Alcian Blue/Nuclear Fast Red for GAG content. Brains 
were also analyzed by staining with Toluidine (neurons), immunohistochemistry 
for GFAP (neuroinflammation) and MOMA-2 (monocyte/macrophage infiltration) 
(see section 3.9 for protocol details). 
 
3.9 PROTOCOLS  
 
3.9.1 Brain capillary depletion 
Brains were separated in the parenchyma and capillary fractions using a dextran 
density centrifugation as previously described by Triguero (Triguero et al., 1990). 
The brain was homogenised at 4° C (about 10 strokes) in 2 times the volume of a 
physiological buffer at pH 7.4, containing: 10 mM HEPES, 141 mM NaCl, 4 nM 
KCl, 2.8 mM CaCl2, 1 mM MgSO4, 1 mM NaH2PO4, and 10 mM D-glucose. Dextran 
solution was then added to a final concentration of 19% and homogenised for a 
further 10 stokes. Homogenate was centrifuged at 5000 g for 15 minutes at 4°C 
and supernatant (parenchyma) and pellet (capillary) were carefully separated. 
 
3.9.2 IDS enzyme assay 
Cell pellet was sonicated in 0.9% NaCl and tissue samples were homogenized in 
0.9% NaCl using a Polytron® PT1200E Disperser (Kinematica AG, Luzern, 
Switzerland); after centrifugation, supernatants were recovered and protein 
concentration determined by the Bradford assay, using the Bio-Rad Protein 
Assay (Bio-Rad Laboratories, Milan, Italy). 
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Blood was collected in heparinized tubes and plasma obtained through 
microcentrifugation at 1000 rcf for 20 minutes; a volume of 10 μl of 5X diluted 
plasma was used to perform the enzyme assay, processed as described below. 
IDS activity was evaluated by performing a fluorometric assay (Vozny et al., 2001) 
employing the substrate 4-methylumbelliferyl-α-iduronide-2-sulfate (MU-αIdu-
2S; Moscerdam Substrates, Erasmus University, Rotterdam, The Netherlands). 
Briefly, 10 μg of protein were assayed by adding 20 μl of 1.25 mM substrate and 
incubating at 37°C for 4h. Afterwards, 20 μl of double concentrated McIlvains 
phosphate/citrate buffer and 10 μl of LEBT (lysosomal enzymes purified from 
bovine testis) were added to each sample and incubated at 37°C for a further 
20h. The reaction was stopped by adding 1440 μl/sample of stop buffer (0.5 M 
NaHCO3/0.5 M Na2CO3, pH 10.7, 0.025% Triton X-100); 4-methylumbelliferone 
(Sigma-Aldrich) was used as standard. Fluorescence was measured in 24-well 
plates on a multi-well reader Victor2 1420 (PerkinElmer, Milano, Italy). Positive 
and negative controls were used in each assay. IDS activity is given in nanomoles 
of substrate hydrolyzed in 4 h per milligram of protein or milliliter of plasma [1 
nmol/4 h/mg (ml) = 1 Unit/mg (ml)]. 
 
3.9.3 Cell/tissue GAG content 
Cell pellet was sonicated in 0.9% NaCl before using it for the assay. Tissue were 
lyophilized, homogenized in 0.9% NaCl + 0.2% Triton X-100 (PanReac AppliChem 
GmbH, Darmstadt, Germany) by a Polytron® PT1200E Disperser (Kinematica AG, 
Luzern, Switzerland), left under stirring overnight at 4°C, centrifuged at 1000 rcf 
for 5 min and the supernatant recovered. 
GAG content was measured by using Bjornsson’s protocol (Bjornsson, 1993), with 
modifications previously described by Friso and colleagues (Friso et al., 2008). 
The assay was performed by diluting 50 µl of blank (water), calibrators 
(chondroitin sulphate C) or samples with an equal volume of 8 M guanidine HCl, 
and then 0.3% H2SO4/0.75% Triton X-100. Samples were incubated o/n at 4°C in 
the presence of Alcian Blue solution. Following centrifugation, pellets were 
washed with 40% DMSO/0.05% MgCl2 and re-suspended in 4 M guanidine 
3. Materials and Methods 
 44 
HCl/33% isopropanol/0.25% Triton X-100. All reagents were purchased from 
Sigma-Aldrich (Milan, Italy). Absorbance was measured at 620 nm in a multi-well 
reader Victor2 1420 (PerkinElmer, Milano, Italy). GAG content was calculated as 
mg GAG/mg protein, and protein content was determined using the Bio-Rad 
Protein Assay (Bio-Rad Laboratories, Milan, Italy). 
 
3.9.4 Urinary GAG content 
Urinary GAG content (calculated as mg GAG per mg creatinine) was determined 
using the protocol described by de Jong and colleagues (de Jong et al., 1992) 
with modifications. GAG content was determined in 24h urine samples, diluted 
1:16, 1:32, 1:64 and mixed with 8 M 1,9-dimethylmethylene blue chloride 
(Sigma-Aldrich, Milano, Italy), 0.05 M Na-formate (Sigma-Aldrich) and 0.18 M 
Tris-HCl (Merck, Milano, Italy) to pH 8.8. A standard curve was prepared using 
chondroitin sulphate type C (Sigma-Aldrich). Absorbance was measured at 520 
nm in a multi-well reader Victor2 1420 (PerkinElmer, Milano, Italy). Urinary 
creatinine was measured by mixing diluted 1:5 and 1:10 urine with picric acid 
(Sigma-Aldrich) diluted 1:5 and 7.5 g/l sodium hydroxide. Absorbance was 
measured at 535 nm and compared with creatinine standard solutions (Sigma-
Aldrich). 
 
3.9.5 Alcian blue and toluidine staining 
Mice were killed and tissues rapidly dissected and fixed for 48h in Bouin’s 
solution. Thereafter, tissues were extensively washed in 70% ethyl alcohol, 
dehydrated through a 70–100% ethanol gradient and paraffin embedded. 
Sections (4 µm) were cut, deparaffinized and stained with: 1% Alcian Blue 
(Sigma-Aldrich) solution pH 1.0 and 0.1% Nuclear Fast Red (Sigma-Aldrich) as 
counterstain; 0.1% Toluidine Blue O (Sigma-Aldrich) solution pH 4.2. All sections 
for the same organ obtained from wild-type, untreated Ids-ko and treated Ids-ko 
mice were stained at the same time. Sections were analyzed without knowing 
the treatments (blind analysis). 
 
3. Materials and Methods 
 45 
3.9.6 Immunohistochemistry and immunofluorescence 
Mice were killed and tissues rapidly dissected and fixed for 48h in Bouin’s 
solution. Thereafter, tissues were extensively washed in 70% ethyl alcohol, 
dehydrated through a 70–100% ethanol gradient and paraffin embedded.  
4 µm thick serial sections were treated for antigen retriever with a 10mM 
sodium citrate buffer pH 6.0 for 15 min at 100°C in a moist environment. The 
specimens were incubated for 1 h with blocking buffer (10% FBS in PBS1X) 
(Gibco, Life technologies) before incubation overnight with the primary 
antibodies. 
For immunohistochemistry a polyclonal rabbit antibody against GFAP (diluted 
1:1000, Novus Biological, Cambridge, UK) was used. Then, a secondary 
AP(alkalin-phosfatse)-conjugated antibody (Life Technologies) was incubated for 
1h. The color was developed for about 15 min using the NBT/BCIP (nitro-blue 
tetrazolium chloride/5-bromo-4-chloro-3'-indolyphosphate p-toluidine salt) 
method (Roche, Milan, Italy). In the end, a counterstain with a 0.5% eosin 
solution was performed and sections mounted with Eukitt® (Sigma-Aldrich). 
For immunofluorescence a rat monoclonal antibody against mouse LAMP2 
(diluted 1:100, ABCAM, Cambridge, UK) was used. Then, a secondary Alexa594-
conjugated antibody (Life Technologies) was incubated for 1h. Stained sections 
were mounted with Fluoromount™ (Sigma-Aldrich) with DAPI (Applichem). 
All sections for the same organ obtained from wild-type, untreated Ids-ko and 
treated Ids-ko mice were stained at the same time. Sections were analyzed 
without knowing the treatments (blind analysis). 
 
3.9.7 Statistical analysis 
Statistically significant differences between groups were determined using 
Student’s t test. Data are presented as mean ± standard deviation. Null 
hypothesis probabilities < 0.05 were considered statistically significant. 
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3.10 MICROSCOPY ANALYSIS 
Confocal analysis (Confocal Microscope Leica DM IRE 2, Bannockburn, IL, USA) 
was performed following the same procedure already reported (Bondioli et al., 
2011). Visible analysis was performed using a Microscope Leica DM 4000B. 
All samples were analysed in multiple procedures and in triplicate for each 
analysis using ImageJ software (http://imagej.nih.gov/ij). In particular, the 
analysis on confocal microscopy was performed by evaluating at least 6-8 optical 
fields (with 20 as average number of nuclei each field) for each sample analysed. 
For each brain, at least 5 slices were analysed. 
Statistical evaluation was performed by using Student’s t-test. Differences were 
considered statistically significant for p < 0.05. 
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4. RESULTS AND DISCUSSION 
 
Drug delivery to the brain represents one of the most stimulating challenges in 
neuro-research, giving the limited number of therapeutics capable to reach the 
CNS. In fact, 98% of the drugs are unable to cross the BBB owing to their high 
molecular weight or chemico-physical properties (Pardridge, 2005). To improve 
drug delivery to the brain, non-invasive techniques have been investigated and, 
among them, the nanotechnology-based approach surely represents one of the 
most promising. 
In this study, we evaluated the ability of polymeric nanoparticles (PLGA-NPs), 
modified with a glycopeptide of 7 amino acids (g7), already tested for molecules 
of low molecular weight, to bypass the BBB and deliver the therapeutic 
recombinant enzymes to the CNS, after systemic administration in the mouse 
models for two diseases, ensuring a prolonged drug release and protection from 
inactivation. 
 
4.1 NPs FEATURES 
All different batches of nanoparticles were prepared and analysed by the 
Te.Far.TI group (Department of Life Sciences, University of Modena and Reggio 
Emilia) in the figure of Dr. Giovanni Tosi and his laboratory, under a project partly 
funded by the CaRiPaRo Foundation (Padova, Italy). 
All the nanoparticles (NPs) used in this study were prepared by the technique of 
water/oil/water (W/O/W) double emulsion, which, as reported in literature, is 
the most suitable for the encapsulation of hydrophilic molecules (Jain, 2000). 
 
4.1.1 NPs for preliminary in vivo experiment with Albumin 
All NPs were characterized in terms of size, surface charge, drug loading and 
surface composition (Table 1). In particular, all NPs, independently from surface 
modification or loading, were featured by dimension under 300 nm, thus 
compatible with a systemic administration, good homogeneity (as PDI values are 
ranging between 0.08 and 0.1 indicating an homogeneous population of NPs) 
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and negative surface charges, as usual when considering PLGA NPs (Tosi et al., 
2007; Vergoni et al., 2009).  
Some differences in chemico-physical parameters could be recognized by 
comparing un-loaded and loaded NPs; in particular, loaded samples, formulated 
at 1:5 drug to polymer molar ratio, were characterized by a significant increase in 
Z-Average diameter (form 230 to 260), probably due to the encapsulation of a 
high MW molecule, but resulting however in an homogeneous size distribution 
(PDI=0.01). In these samples, ζ-pot slightly decreased (about -22 mV) probably 
for the different reorganization of polymer chains in the presence of loaded 
albumin. 
 
Samples 
Z-Averagea 
nm (±S.D) 
PDIa 
(±S.D) 
Di50a 
nm 
(±S.D) 
Di90a 
nm 
(±S.D) 
-pota 
mV  
(±S.D) 
mg of FITC 
Alb/100 mg 
NPs (±S.D) 
EE%b 
(±S.D) 
N/C 
ratio 
u-NPs 221 (7) 
0.08 
(0.02) 
230 (9) 330 (4) -16 (4) / / 0.010 
g7-NPs 234 (8) 
0.11 
(0.03) 
231 (5) 335 (9) -14 (3) / / 0.024 
u-NPs/Alb 260 (7) 
0.11 
(0.03) 
275 (5) 480 (8) -21 (5) 10.4 (1.1) 50 (5) 0.012 
g7-NPs/Alb 261 (8) 
0.08 
(0.02) 
268 (4) 375 (9) -24 (4) 7.3 (0.1) 36 (4) 0.025 
 
Table 1: chemico-physical characterization of nanoparticles.  
PDI means Poly dispersity index, -pot represents zeta potential indicating surface charge, EE is 
encapsulation efficiency. N/C is reported for each sample where C represents the percentage of 
Carbon signals onto NPs surface and N represents Nitrogen signals. As commonly accepted, when 
the molecule (i.e. g7 peptide) modifying the surface of NPs is rich of N, the presence of N signals 
onto NPs surface is considered as the proof of the surface engineering. The lower is the N/C value 
the lower is the presence of the molecule modifying the NPs surface.Di50 and Di90 are referring 
to dimensional distribution values (50 and 90). 
aValues are given as mean±S.D. (n=9) 
bThe percentage of encapsulation efficiency was determined as the ratio of the encapsulated out 
of the total (encapsulated + free) drug per cent (%). Values are intended as mean±S.D. (n = 9). 
 
4. Results and Discussion 
 49 
Percent of loading efficiency (EE%) of u-NPs and g7-NPs is quite different, with a 
decrease in Alb content of about 30% in g7-NPs/Alb with respect to u-NPs/Alb. 
This data is not surprising, since the loading process with Alb represents the first 
step in the formulation of NPs, followed by activation of NPs and conjugation 
with peptides, suspended and stirred in aqueous medium, thus leading to a 
possible lost in drug content (Bondioli et al., 2011). 
Interestingly, the surface analysis of NPs by ESCA described the presence of g7 
onto NPs surface, as confirmed by an increased nitrogen/oxygen ratio in g7-NPs 
(both unloaded and loaded with Alb). As expected, the same data were not 
recovered for un-modified NPs, and this nicely correlates with previous reports 
on the surface engineering of PLGA NPs (Nobs et al., 2006; Hao Yan et al., 2012; 
Nobs et al., 2004; Nobs et al., 2003). The analysis conducted on the activated NPs 
(intermediate step of formulation obtained by neutravidin activation) did not 
show a significant increase in N/C ratio with respect to un-modified NPs (i.e. N/C 
ratio=0.12) (data not shown) as previously reported (Nobs et al., 2006; Hao Yan 
et al., 2012; Nobs et al., 2004; Nobs et al., 2003). This confirmed that the amount 
of nitrogen onto activated NPs is negligible with respect to that derived from g7 
surface modification.  
From a morphological point of view, AFM (Atomic Force Microscopy) and SEM 
(Scanning Electron Microscopy) (Figure 1a and 1b) analyses confirmed that 
unloaded samples were formed by spherical structures with diameter in 
agreement with photon correlation spectroscopy (PCS) data and regular surface. 
Considering loaded NPs, microscopic examination, and particularly AFM outputs, 
displayed more complicated structures. Although still spherical, u-NPs/Alb 
showed a discontinuous and rough surface (Figure 1c). On the opposite, g7-
NPs/Alb appeared with a more regular and homogeneous surface; this fact is 
likely to be attributed to the surface modification process, when the adsorbed 
FITC-albumin is partially removed and washed from the NPs surface. This finding 
is also evident by the content analysis previously exposed, evidencing a decrease 
of Alb content in g7-NPs versus u-NPs. Moreover, a slight tendency to 
4. Results and Discussion 
 50 
aggregation, once on mica surface, could be highlighted in the case of g7-NPs, 
probably due to the presence of neutravidin and g7 on the surface (Figure 1e). 
 
 
Figure 1: Morphologic characterization of nanoparticles. Left columns (panels a,c,e) AFM and 
right column (panel b, d, f) SEM images of unloaded g7-NPs as control and loaded u-NPs/Alb and 
g7-NPs/Alb. 
 
4.1.2 NPs for in vitro and in vivo experiment with IDS 
All NPs were characterized in terms of size, surface charge and drug loading 
(Table 2). In particular, all NPs, independently from surface modification or 
loading, were featured by dimension under 250 nm, thus compatible with a 
systemic administration, good homogeneity and negative surface charges, as 
usual when considering PLGA NPs (Tosi et al., 2007; Vergoni et al., 2009). Percent 
of loading efficiency (EE%) of u-NPs-IDS and g7-NPs-IDS is quite different, with a 
decrease in IDS content of about 50% in g7-NPs-IDS with respect to u-NPs-IDS. As 
underlined in the previous paragraph, this data is not surprising, since the 
loading process with IDS happens as first step in the formulation of NPs, thus 
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leading to a possible lost in drug content in the subsequent steps (Bondioli et al., 
2011). 
 
Samples Z-Averagea nm PDIa -pota mV mg of IDS/100 mg NPs EE%b  
u-NPs-IDS 207 0.19 -36 3.1 31% 
g7-NPs-IDS 207 0.214 -34 1.5 15% 
g7-NPs-IDS-R 227 0.162 -36 1.65 16.5% 
 
Table 2: chemico-physical characterization of nanoparticles loaded with recombinant IDS. PDI 
means Poly dispersity index, -pot represents zeta potential indicating surface charge, EE is 
encapsulation efficiency. 
 
4.2 IN VIVO PRELIMINARY STUDIES OF g7-NPs IN MPS I AND MPS II MOUSE 
MODELS 
 
4.2.1 In vivo preliminary study in the MPS I mouse model 
Baseline experiments, aimed to confirm in the MPS I animal model results 
previously obtained in the wt mouse (Tosi et al., 2007; Tosi et al., 2014; Vilella et 
al., 2014; Tosi et al., 2013a; Tosi et al., 2013b; Tosi et al., 2013c), included 
injection of 2 mg/animal of g7-NPs in the tail vein of Idua-ko and wt mice (n=3), 
as well as 2 mg/animal of u-NPs in the same mice (n=3). As shown in Figure 2 
and 3, results confirmed for the Idua-ko mouse model and for the syngeneic wt 
control, an efficient g7-NPs crossing of the BBB, with a higher efficiency, of about 
5.5 fold, for the Idua-ko (mean value: 1641 g7-NPs per optical field) vs the wt 
mouse (mean value: 288 g7-NPs per optical field).  
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Figure 2: number of NPs per optical field in the brain of the Idua-ko mouse model and in the 
syngeneic wt control.Type of treatments: g7-NPs = un-loaded and targeted NPs; u-NPs = un-
loaded and un-targeted NPs; Alb = Albumin; g7-NPs/Alb = targeted NPs loaded with albumin; u-
NPs/Alb = un-targeted NPs loaded with albumin; MIX1 (g7-NPs+Alb) = un-loaded targeted NPs 
suspended in FITC-albumin solution; MIX2 (u-NPs+Alb) = un-loaded and un-targeted NPs 
suspended in FITC-albumin solution. n=3-5 for all type of injection. 
 
On the opposite, u-NPs BBB crossing looks extremely poor or totally absent in 
our wt mouse (mean value: 12 u-NPs per optical field), as previously shown in 
other mouse strains, and slightly higher in the Idua-ko mouse, although still very 
low (mean value: 21 u-NPs per optical field).  
BBB status in LSDs was previously investigated especially in the MPS III condition 
(Garbuzova-Davis et al., 2013; Garbuzova-Davis et al., 2011; Begley et al., 2008): 
endothelial cells damage with possible compromise of the BBB was described 
indicated, among others, by Evans Blue and albumin microvascular leakage in 
various brain structures. On the opposite, a similar analysis conducted in this 
work for both wt and Idua-ko mice, by using Evans Blue (see Section 4.3) and 
FITC-albumin, detected no altered permeability, thus suggesting possible altered 
uptake pathways. This hypothesis is supported by the fact that also in the liver a 
higher efficiency of uptake in the Idua-ko vs wt mouse was found (Figure 4). 
Therefore, similarly to what previously reported with the brain-targeted (with 
receptor binding peptide for ApoE3) pro-drug of the therapeutic enzyme (α-L-
iduronidase) (Wang et al., 2013), NPs, although with remarkable differences in 
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terms of success (g7-NPs˃˃u-NPs), could take advantage of the improved 
transcytotic pathways to reach Idua-ko brains. 
 
 
Figure 3: Brains of the Idua-ko and wt mice injected with targeted and untargeted unloaded 
PLGA-NPs. a) Idua-ko injected with g7-NPs; b) wt injected with g7-NPs; c) Idua-ko injected with u-
NPs; d) wt injected with u-NPs. 
4. Results and Discussion 
 54 
 
Figure 4: Livers of a) Idua-ko and b) wt mice injected with g7-NPs/Alb. Magnification: 40-60 x. 
From the left: blue DAPI staining (nuclei), red NPs, due to rhodamine labeling, green FITC labeling 
of Alb and the last one is the merge image. 
 
We next administered targeted nanoparticles loaded with albumin (g7-NPs/Alb) 
in both animal types (Idua-ko n=3, wt n=4) to evaluate efficiency of g7-NPs BBB 
crossing as well as ability to carry over the albumin. As shown in Figure 5, there is 
a co-localization of g7-NPs and albumin in both animal types, thus demonstrating 
for the first time that g7-NPs can carry high MW molecules, as albumin, through 
the BBB. Moreover, Figure 2 shows how the number of g7-NPs/Alb per optical 
field is much higher in Idua-ko than in wt mice, about 4.4 fold. As control, the 
administration of free albumin solution (0.2 mg/mouse) in Idua-ko and wt mice 
(both n=3) did not lead to any significant signals of albumin, thus excluding the 
possibility of FITC-albumin BBB crossing and also confirming, indirectly, the 
maintenance of BBB integrity and impermeability to high MW molecules in Idua-
ko mice (not shown).  
As further control, we also injected un-targeted NPs loaded with albumin (u-
NPs/Alb) in Idua-ko and wt mice (both n=3). As expected, the extent of BBB 
crossing is almost non-existent in both animal types (17 and 9 u-NPs/Alb per 
optical field in Idua-ko and ko mice, respectively) (Figure 2 and 5), confirming 
that the g7-targetor moiety is needed to allow brain targeting of PLGA-NPs, as 
well as brain delivery of the loaded Alb. 
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To consider whether Alb adsorbed onto NPs (targeted or not) can be driven 
across the BBB, we additionally injected Idua-ko (n=4) and wt (n=3) mice with un-
loaded g7-NPs suspended in free FITC-albumin (MIX1). Unexpectedly, as shown 
in Figure 2 and 6a, we observed that albumin could cross the BBB also if 
administered as MIX1; as supposed, the perfect co-localization of Alb and NPs 
suggests that Alb likely binds externally to the surface of the NPs and is carried 
into the CNS together with the NPs. This result is not surprising as it was 
hypothesized for other types of NPs able to transfer into the CNS high MW 
molecules, which were both adsorbed onto NPs surface and loaded into NPs 
(Wohlfart et al., 2012). 
As supposed, the injection of un-loaded u-NPs suspended in free FITC-albumin 
(MIX2), did not lead to any Alb signal in the CNS, confirming the inability of un-
targeted NPs to cross the BBB thus delivering any adsorbed material (as Alb) 
(Figure 6b). 
 
 
Figure 5: Brains of the Idua-ko and wt mice injected with a) g7-NPs/Alb and b)u-NPs/Alb. 
Magnification 40-60x. 
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Figure 6: Brains of the Idua-ko and wt mice injected with: a) MIX1 (g7-NPs+Alb), b) MIX2 (u-
NPs+Alb). 
 
In conclusion, there is a higher, statistically significant, amount of g7-NPs (p-
value=0.0002) and g7-NPs/Alb (p-value=0.0007) that can cross the BBB with 
respect to u-NPs and u-NPs/Alb respectively. This provides excellent 
prerequisites for the use of these g7-NPs with the recombinant enzymes, as well 
as with other high molecular weight molecules, to treat neurological diseases. 
 
4.2.2 In vivo preliminary study in the MPS II mouse model 
Efficiency of g7-NPs/Alb BBB crossing was afterwards evaluated in the MPS II 
mouse model (Ids-ko). These experiments aimed to extend the potential use of 
this kind of carriers to transport high molecular weight therapeutic molecules to 
the brain district in other LSDs and hopefully many other neurological disorders. 
As show in Figure 7, g7-NPs/Alb can cross BBB also in the Ids-ko mouse model 
and, as already seen in the Idua-ko mice, and shown in Figure 8, we found a 
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significantly higher (p-value = 1.52E-07) number of NPs per optical field in the 
Ids-ko than in the wt mice (both n=5), about 3.6 fold. 
In this case, the extent of g7-NPs/Alb reaching the brain is significantly lower (1.5 
fold, p=0.006) with respect to Idua-ko mice and this might be due to a different 
BBB permeability or modified processes in BBB crossing pathways in the two 
different animal models or pathologies. This finding represents an open question 
regarding the different status of the BBB in very similar pathologies (MPS I, MPS 
II and MPS III), but with different outputs in terms of BBB crossing and 
endothelial dynamic damage. Moreover, it is important to note that in these 
experiments we did not monitor crossing efficiency with the progression of the 
pathology and further experiments will be targeted to check whether g7-NPs 
BBB crossing in LSDs-ko mice may be function of the disease progression (from 
early to late stage).    
As a control, we also injected free albumin in Ids-ko and wt mice (n=3) and the 
results confirmed that albumin cannot cross BBB in both mice (not shown). 
 
 
Figure 7: Ids-ko mouse model and syngeneic wt injected with g7-NPs/Alb. Magnification 20X.  
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Figure 8: number of NPs per optical field in the brain of the Ids-ko mouse and syngeneic wt, 
injected with g7-NPs/Alb. 
 
4.3 CHECKING OF BBB INTEGRITY 
To exclude that the higher g7-NPs/Alb uptake in the ko mouse models may be 
due to possible damages in their BBB, we performed experiments aimed to check 
BBB integrity. To this aim we injected Idua-ko, Ids-ko and the respective wt mice 
with Evans Blue solution (Deng et al., 1998); none of the animals showed a BBB 
crossing of the dye, this indicating an undamaged BBB. Therefore, the difference 
in the NPs uptake may hypothetically reside in other factors, as a different 
expression of transporters on the endothelium as well as a modification in the 
endocytosis process in both ko mice vs wt controls. As previously reported in 
section 4.2.1, also the results obtained in the liver support this hypothesis. 
Therefore, more studies will be necessary to understand what leads to the 
difference in the uptake of NPs and, most of all, to understand the basic 
differences in the BBB composition/structure of both ko animals vs the related 
wt mice. 
 
4.4 IN VIVO PRELIMINARY STUDY OF g7-NPs-IDS-R IN MPS II MOUSE MODEL 
To confirm that g7-NPs can transport IDS through the BBB, a preliminary study 
was conducted using g7-NPs loaded with recombinant IDS (Elaprase®, Shire 
Human Genetic Therapies, Inc, Cambridge, MA, USA) and marked with 
Rhodamine B (g7-NPs-IDS-R).  
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As shown in Figure 9, g7-NPs-IDS-R can cross BBB both in the wt and Ids-ko mice 
and, as already seen for g7-NPs/Alb, we found a significantly higher (p-value = 
0.03) number of NPs per optical field in the Ids-ko than in the wt mice (both 
n=3), about 3.4 fold. 
However, IDS enzyme assay carried out in 3 Ids-ko and 3 wt mice showed an 
induced activity equal to zero in all tested animals (data not shown). 
Consequently, we can hypothesize that nanoparticles may take longer than 2 
hours to open up and release the encapsulated enzyme. To assess this 
hypothesis, in vitro and in vivo studies were necessary to evaluate possible times 
of enzyme release. 
 
 
 
 
Figure 9: wt (a) and syngeneic Ids-ko mouse model (b) injected with targeted NPs loaded with IDS 
enzyme and labeled with Rhodamine B (g7-NPs-IDS-R). Arrows indicate g7-NPs-IDS-R. 
Magnification 40X with respective 3X digital zoom. c) number of NPs per optical field in the brain 
of the Ids-ko mouse and syngeneic wt, injected with g7-NPs-IDS-R. 
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4.5 IN VITRO ANALYSIS OF u-NPs-IDS EFFICACY 
To verify NPs capability to encapsulate the recombinant enzyme and transport it 
to the cells, maintaining its therapeutic efficacy, an in vitro study was conducted 
on primary fibroblasts obtained from MPS II patients and healthy human 
controls. 
Cells were treated with free recombinant IDS, IDS encapsulated in NPs (u-NPS-
IDS) or remained untreated. Fibroblasts were treated for 7 days, then the 
treatment was removed and cells sacrificed after 0, 7 and 14 days.  
The in vitro analysis confirmed the ability of NPs to load the IDS recombinant 
enzyme and transport it into the cells, maintaining its activity. 
Although cells treated with the u-NPs-IDS showed a lower activity with respect to 
the ones treated with free enzyme (Figure 10), this was similar to that measured 
in healthy control cells and sufficient to reduce the content of GAG to non-
pathological levels (Figure 11).  
These data suggest that nanoparticles may need more time to open up and 
release the recombinant enzyme or, otherwise, that they may need a more 
complex physiological system with respect to the in vitro one. 
Since data were promising, but it was impossible to prolong the time of the in 
vitro test for technical reasons, evaluation on the nanoparticles efficacy was 
turned to the mouse model. 
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Figure 10: IDS activity (nmol/4h/mg protein) induced after 7days of treatment in cells from MPS 
II patients. Type of treatment: free recombinant IDS (IDS), unmodified NPs loaded with 
recombinant IDS (u-NPs-IDS), untreated MPS II fibroblast (UT). The solid line is the reference 
value of cells from healthy patients (healthy). Evaluation was carried out0, 7 and 14 days after 
the end of the treatment. Activities expressed in nmoles of 4MU (4-Methylumbelliferil-α-L-
iduronide-2-sulphate.Na2) produced in 4 hours per mg of protein.*p<0.05 
 
 
 
Figure 11: GAG content (µg GAG/mg protein) after 7days of treatment in cells from MPS II 
patients. Type of treatment: free recombinant IDS (IDS), unmodified NPs loaded with 
recombinant IDS (u-NPs-IDS), untreated MPS II fibroblast (UT). The solid line is the reference 
value of cells from healthy patients (healthy). Evaluation was carried out 0, 7 and 14 days after 
the end of the treatment.*p<0.05 
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4.6 IN VIVO PILOT STUDY IN THE MPS II MOUSE MODEL 
To evaluate transfer efficiency and the enzymatic activity induced by g7-NPs 
loaded with the recombinant enzyme (g7-NPs-IDS), an in vivo pilot study in the 
MPS II mouse model was first conducted. 
As observed in the in vitro experiments, NPs (targeted or not) were able to 
deliver the recombinant IDS enzyme, although a very low plasmatic IDS activity 
was induced by the treatment with respect to what induced by the free IDS 4h 
after injection (Figure 12). After 24 hours, the enzymatic activity induced by NPs 
was practically undetectable, while it was still substantial for free IDS treated 
mice. 
A similar situation was also found in the liver after 7 days, where the induced 
enzymatic activity could be detected for the Ids-ko mice treated with free IDS, 
but it was almost non-existent for those treated with NPs (targeted or not) 
(Figure 13).This was also confirmed by the results obtained from the evaluation 
of the GAG content in the liver, which was found reduced after 7 and 14 days for 
mice treated with free IDS, but not for those treated with NPs (Figure 14). 
Differently from what expected for g7-NPs-IDS, but in line with the results of the 
liver, induced IDS activity was not detected in the brain parenchyma for all types 
of treatment (Figure 15). 
 
Figure 12: IDS activity (nmol/4h/ml) detected after 4 hours (4h), 24 hours (24 hours), 7 days (7d) 
and 14 days (14d) in the plasma of Ids-ko mice treated with free IDS, u-NPs-IDS and g7-NPs-IDS, 
compared with the activity detected in the plasma of untreated  Ids-ko (UT)and wild-type (wt) 
mice. Activities expressed as nmoles of 4MU (4-Methylumbelliferil-α-L-iduronide-2-sulphate.Na2) 
produced in 4 hours per ml of plasma. *p<0.05 
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Figure 13: IDS activity (nmol/4h/mg protein) detected after 7 and 14 days in the liver of Ids-ko 
mice treated with free IDS, u-NPs-IDS and g7-NPs-IDS, compared with the untreated Ids-ko (UT) 
and wild-type (wt) mice. Activities expressed as nmoles of 4MU (4-Methylumbelliferil-α-L-
iduronide-2-sulphate.Na2) produced in 4 hours per mg of protein. *p<0.05 
 
 
Figure 14: GAG content (µg GAG/mg protein) detected after 7 and 14 days in the liver of Ids-ko 
mice treated with free IDS, u-NPs-IDS and g7-NPs-IDS, compared with the untreated Ids-ko (UT) 
and wild-type (wt) mice. *p<0.05 
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Figure 15: IDS activity (nmol/4h/mg protein) detected after 7 and 14 days in the brain 
parenchyma of Ids-ko mice treated with free IDS, u-NPs-IDS and g7-NPs-IDS, compared with the 
untreated Ids-ko (UT) and wild-type (wt) mice. Activities expressed as nmoles of 4MU (4-
Methylumbelliferil-α-L-iduronide-2-sulphate.Na2) produced in 4 hours per mg of protein. 
*p<0.05 
 
All these data could be explained by the need of a longer time for nanoparticles 
to open up and release the encapsulated enzyme. To date there are still no 
conclusive studies in the medium/long term with this type of NPs and the time of 
release of the incorporated molecules is therefore still undefined. 
The IDS activity detected in the plasma for both types of NPs can be justified by a 
possible external binding of the recombinant enzyme to the surface of the NPs. 
This is not surprising as it was hypothesized for other types of NPs able to 
transfer high MW molecules, which were both adsorbed onto NPs surface and 
loaded into NPs (Wohlfart et al., 2012). 
 
4.7 IN VIVO MEDIUM-TERM EFFICACY STUDY IN THE MPS II MOUSE MODEL 
Although the results obtained in the in vitro and in vivo pilot studies were mostly 
negative, it was important to carry out a medium-term analysis to assess the 
possible opening of NPs in a longer time.  
With this aim, an in vivo study was conducted in the MPS II mouse model, by 
treating mice once a week for 6 weeks. 
After 6 weeks treatment, mice (8 untreated Ids-ko, 8 Ids-ko treated with g7-NPs-
IDS and 8 wt) were sacrificed and used for biochemical as well as histological, 
immunohistochemical and immunofluorescence evaluations. 
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4.7.1 Biochemical evaluations 
Induced IDS activity was evaluated in liver (Figure 16) and brain parenchyma 
(Figure 17) of 5 mice/treatment. An increased enzyme activity was detected only 
in livers of free IDS treated mice; however, although not significant, a slight trend 
of increasing enzyme activity could be seen in the brain parenchyma of mice 
treated with g7-NPs-IDS. These data suggest that a period of 6 weeks is again too 
short to detect the opening of these NPs and the release of the encapsulated 
enzyme, although some NPs have probably opened.  
Data obtained from the biochemical evaluation of tissue GAG levels partially 
confirm this hypothesis. Figure 18 and 19 show, respectively, GAG content 
detected in liver and brain parenchyma of the same mice. In the liver a 
significant decrease of GAG content (about 30%) in mice treated with g7-NPs-IDS 
compared to untreated Ids-ko mice was detected, although this decrease is 
much lower than that observed in free IDS treated mice (about 95%). In the brain 
parenchyma no significant GAG decreases were detected; however, a slight 
trend in this direction could be seen in the brain parenchyma of mice treated 
with g7-NPs-IDS. Probably a decrease was significant detected only in the liver, 
though activity was not recorded, since liver is the organ usually receiving the 
largest amount of drug, therefore even the little amount of enzyme released by 
the NPs was rapidly taken up by the cells with a consequent reduction of the 
storage material. 
Figure 20 shows the urinary GAG content before and after 6 weeks of treatment. 
Respect to the starting point and to UT mice, only free IDS treated mice have 
shown a decreased GAG content. Again, the little amount of enzyme released by 
NPs was likely insufficient to reduce GAG accumulated in the organs as well as to 
obtain a reduction of urinary GAG. 
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Figure 16: IDS activity (nmol/4h/mg protein) detected in the liver after 6 weeks of treatment in 
Ids-ko mice treated with free IDS and g7-NPs-IDS, compared with untreated (UT) Ids-ko and wild-
type (wt) mice (n=5 for each treatment). *p<0.05 
 
 
Figure 17: IDS activity (nmol/4h/mg protein) detected in the brain parenchyma after 6 weeks of 
treatment in Ids-ko mice treated with free IDS and g7-NPs-IDS, compared with untreated (UT) 
Ids-ko and wild-type (wt) mice (n=5 for each treatment). *p<0.05 
 
 
Figure 18: GAG content (µg GAG/mg protein) detected in the liver after 6 weeks of treatment in 
Ids-ko mice treated with free IDS and g7-NPs-IDS, compared with untreated (UT) Ids-ko and wild-
type (wt) mice (n=5 for each treatment). *p<0.05 
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Figure 19: GAG content (µg GAG/mg protein) detected in the brain parenchyma after 6 weeks of 
treatment in Ids-ko mice treated with free IDS and g7-NPs-IDS, compared with untreated (UT) 
Ids-ko and wild-type (wt) mice (n=5 for each treatment). *p<0.05 
 
 
Figure 20: Urinary GAG content (mg GAG/mg creatinine) detected before starting (PRE) and at 
the end after 6 weeks of treatment in Ids-ko mice treated with free IDS and g7-NPs-IDS, 
compared with untreated (UT) Ids-ko and wild-type (wt) mice (n=8 for each treatment). *p<0.05 
 
4.7.2 Histological, immunohistochemical and immunofluorescence evaluations 
Brains and livers were fixed for 48h in Bouin’s solution and processed for paraffin 
embedding. The results of histochemical analysis for GAG deposits in liver and 
brain are shown in Figure 21 and 22, respectively. 
As previously reported in the literature (Friso et al., 2010), in the liver of 
untreated Ids-ko animals, accumulation of undegraded GAGs was observed in 
the Glisson’s capsule and in the layer of mesothelial cells (Figure 21a), as well as 
around the portal tract and in the extracellular matrix of hepatocytes (Figure 
21b, blue arrow); some hepatic lobules showed a vacuolated structure (Figure 
21b, yellow arrow). The same accumulation was found also in the liver of Ids-ko 
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mice treated with g7-NPs-IDS, although at a visible lower extent (Figure 21c and 
21f). These data confirmed those obtained by the biochemical analysis of GAG 
content in the same organ, stressing again the ability of g7-NPs-IDS to reduce the 
accumulation of GAG, although not normalizing them to the level of healthy 
animals. 
 
 
Figure 21: Histochemical analysis of glycosaminoglycan (GAG) in the liver of wt mice (a,d), 
untreated Ids-ko mice (b,e) and Ids-ko mice treated with g7-NPs-IDS (c,f) after 6 weeks of 
treatment. Representative sections of the external surface (a,b,c) and of a portal tract (d,e,f). 
Blue arrows indicate GAG deposits, yellow arrows indicate vacuolated structures. Sections (4μm) 
were stained with 1% Alcian Blue, counterstained with 0.1% Nuclear Fast Red. Magnification 40X. 
 
Neuropathological defects were described for the MPS II mouse model as cellular 
vacuolization in different brain regions (Cardone et al., 2006) and as neuronal 
necrosis in the brainstem and spinal cord (Garcia et al., 2007). As previously 
described for the mouse model of MPS IIIB (Fu et al., 2007), the animal model for 
MPS II showed lower accumulation of GAG in the brain, compared with other 
tissues when a biochemical analysis was performed. Approximately, a twofold 
increase in GAG levels compared to wild-type mice was previously described 
(Garcia et al., 2007; Friso et al., 2010) and here confirmed (Figure 19).  
Histochemical analysis of brain GAG content is presented in Figure 22. As 
previously reported (Cardone et al., 2006), the major areas of GAG accumulation 
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in Ids-ko brain was within the third (Figure 22e) and fourth (Figure 22h) 
ventricles, and at a lower extent in the cerebral cortex (Figure 22b). The same 
deposits were visible also in the brain of Ids-ko mice treated with g7-NPs-IDS, 
although at a slightly lower level (Figure 22c,f,i).These data confirmed the ones 
obtained by the biochemical analysis of GAG deposits in the same organ, 
indicating a slight downward trend of accumulation although not statistically 
significant. 
Figure 23 shows representative sections of the cerebellum stained with 0.1% 
toluidine solution. As shown in the digital zoom, the Purkinje cells were 
vacuolated both in untreated and treated Ids-ko mice, indicating that the little 
amount of enzyme released by the nanoparticles was insufficient to improve or 
correct the damage at this level. 
 
 
Figure 22: Histochemical analysis of glycosaminoglycan (GAG) in the brain of wt mice (a,d,g), 
untreated Ids-ko mice (b,e,h) and Ids-ko mice treated with g7-NPs-IDS (c,f,i) after 6 weeks of 
treatment. Representative sections of the cortex (a,b,c), the choroid plexus (d,e,f) and the 
cerebellum (g,h,i). Arrows indicate GAG deposits. Sections (4 μm) were stained with 1% Alcian 
Blue, counterstained with 0.1% Nuclear Fast Red. Magnification 20X (a,b,c,d,e,f) and 10X (g,h,i). 
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Figure 23: Histochemical analysis of the brain of wt mice (a), untreated Ids-ko mice (b) and Ids-ko 
mice treated with g7-NPs-IDS (c) after 6 weeks of treatment. Representative sections of the 
cerebellum stained with 0.1% toluidine solution.  Arrows indicate vacuolated Purkinje cells. 
Magnification 40X and relative digital zoom of the Purkinje cells. 
 
To observe the size of the late endosomal/lysosomal compartment and hence to 
measure the amount of lysosomal storage, sections of paraffin embedded-brain 
were stained with lysosomal associated membrane protein 2 (LAMP2) (Figure 
25). As shown in the panel, positive lysosomal signals were detected in all the 
three areas of the brain in both untreated and treated Ids-ko mice. The number 
of positive cells to LAMP2 per total number of cells (Figure 25j) showed a slight 
tendency to decrease in the hippocampus and cortex of the animals treated with 
g7-NPs-IDS, and although not significantly, this was coherent with the other data 
obtained from biochemical and histological/immunohistochemical analysis. 
To determine whether nanoparticles could reduce neuroinflammation in Ids-ko 
mice, we counted the number of positive astrocytes for GFAP (a neuromarker for 
astrogliosis) in the cerebral cortex, in the hippocampus and in the cerebellum 
(Figure 24). Ids-ko mice exhibit a marked increase in neuroinflammatory 
astrocytes compared to wt. g7-NPs-IDS seemed to slightly reduce GFAP-positive 
astrocytes in the cerebellum, although not significantly, but not in the cerebral 
cortex and in the hippocampus. 
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Figure 24: Immunohistochemical analysis of GFAP in the brain of wt mice (a,d,g), untreated Ids-
ko mice (b,e,h) and Ids-ko mice treated with g7-NPs-IDS (c,f,i) after 6 weeks of treatment. 
Representative sections of the cortex (a,b,c), the hippocampus (d,e,f) and the cerebellum (g,h,i) 
(magnification 40X).j shows the % of positive cells to GFAP in wt mice and Ids-ko mice treated 
with g7-NPs-IDS with respect to untreated Ids-ko mice (UT=100%). 
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Figure 25: Immunofluorescence analysis of LAMP2 in the brain of wt mice (a,d,g), untreated Ids-
ko mice (b,e,h) and Ids-ko mice treated with g7-NPs-IDS (c,f,i) after 6 weeks treatment. 
Representative sections of the cortex (a,b,c), the hippocampus (d,e,f) and the cerebellum (g,h,i) 
(magnification 40X). j shows the number of positive cells to LAMP2 per total number of cells. 
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Results obtained from this medium-term study are encouraging as they show a 
slight trend towards improvement in brain and liver of g7-NPs-IDS treated mice 
assessed with most of the techniques applied. 
Based on their formulation, it is expected that nanoparticles gradually release 
the encapsulated enzyme, likely providing it in low doses, although more 
constant and prolonged in time with respect to the free IDS. Therefore, even in 
the phase of maximum release of the enzyme, it is expected that the activity 
detected in peripheral organs, as liver, will be likely lower than that induced by 
the administration of free enzyme. 
However, this assumption is not sufficient to explain the results obtained in this 
medium-term study, as the efficacy results here obtained also suggest that 6 
weeks of treatment are likely insufficient to observe the release of the 
encapsulated enzyme in a therapeutic amount. 
To conclude, longer studies would be necessary to understand the timing of 
release of the enzyme from this kind of NPs. However, the main point will be to 
rethink about the formulation of nanoparticles, in order to obtain the generation 
of other NPs with the same transport efficiency to the CNS, but with shorter 
times of release. 
To this purpose, the group of the University of Modena collaborating with us in 
this project, is already working to constitute softer nanoparticles, that will be 
likely more easily biodegradable, therefore characterized by shorter opening 
times and consequent faster release of the encapsulated therapeutic molecules. 
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5. CONCLUSIONS 
 
Lysosomal Storage Disorders are a group of neurometabolic syndromes, mostly 
due to the deficit of one lysosomal enzyme. Many LSDs affect most of the organ 
systems and about two-thirds of the patients present neurological and cognitive 
impairment.  
Among these, Mucopolysaccharidoses type I and type II are both characterized 
by a lack of activity of lysosomal enzymes involved in the catabolism of the 
glycosaminoglycans heparan- and dermatan-sulfate, therefore accumulating in 
the cell compartment and in the extracellular matrix. To date the available 
therapeutic options for these MPSs are mainly based on ERT; however, the 
neurological involvement is unlikely to benefit from this kind of treatment. In 
fact, although positive results have been reported in the animal models following 
ERT in neonates (Urayama et al., 2004; 2008) or using doses far higher those 
conventionally used in clinical treatment (Vogler et al., 2005; Tomatsu et al., 
2007), with the current dosages and formulation, diffusion of the proteins 
involved in ERT across the BBB is almost non-existent (Boado et al., 2008).  
This problem deserves a solution and would suggest the use of modified 
enzymes or vehicle able to cross the BBB. 
In general, clinical efficacy of conventional therapies for neurological diseases is 
in most cases limited by the ability of the drugs to reach the cerebral district. In 
addition, the rapid removal from the bloodstream decreases the bioavailability 
and reduces the amount usable for the target site. 
Recent studies show that carriers as the engineered nanoparticles may cross the 
BBB without damage (Tosi et al, 2007; Tosi et al., 2014; Vilella et al., 2014; Tosi et 
al., 2013a; Tosi et al., 2013b) and carry drugs and genetic material to the brain, 
thus being considered as potential strategies to implement the treatment of 
brain disorders. Therefore, it is hopefully that the use of nanotechnologies, able 
to protect their content and to carry therapeutics to the CNS, fits perfectly with 
the need to carry specifically to this district the recombinant enzymes, necessary 
to correct neurological involvement in some LSDs. Moreover, the features of g7-
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NPs, as internalization and up-take by neurons by the clathrin pathway, 
submission to an intracellular trafficking based on Rab5 and accumulation in the 
lysosomes (Tosi et al., 2014; Vilella et al., 2014; Chhabra et al., 2014), could 
represent a plus, since the deficient enzyme needs to be transported to the 
organelle where the pathological storage is metabolized. 
To this aim, in this study preliminary experiments were conducted using g7-NPs 
loaded with the model drug FITC-albumin or the recombinant IDS enzyme and 
labelled with Rhodamine B, demonstrating that g7-NPs can transport high 
molecular weight molecule such as enzyme through the BBB and paving the way 
for the upcoming in vitro and in vivo efficacy studies. 
However, in vitro and in vivo pilot studies suggested that nanoparticles might 
need more than 2 weeks to open up and release the recombinant enzyme. 
Indeed, to date there are still no conclusive studies in the medium/long term 
with this type of NPs and the time of release of the incorporated molecules is 
thus still undefined. 
Therefore, it was important to carry out a medium-term analysis to assess the 
possible opening of NPs in a longer time. Biochemical, histological, 
immunohistochemical and immunofluorescence evaluation in liver and brain of 
g7-NPs-IDS treated mice suggested that a period of 6 weeks is again too short to 
detect the opening of the NPs and the release of the encapsulated enzyme. 
However, results obtained from this medium-term study are encouraging as they 
show a slight trend towards improvement in brain and liver of g7-NPs-IDS 
treated mice. 
Starting from this study, we can conclude that further studies, at the moment 
ongoing, are needed to understand the timing of release of the enzyme from the 
NPs; in addition, we are re-formulating the nanoparticles with the aim to 
maintain the same transport efficiency to the CNS, although allowing a 
significant reduction of the timing of drug release. For example, nanoparticles 
with cholesterol in the formulation would be likely more easily biodegradable 
and with shorter opening and releasing times. 
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In conclusion, delivery of recombinant enzymes through nanoparticles may 
represent a prototype of the transfer of other high molecular weight molecules 
that may be conveyed, thereafter, to the brain, allowing a more targeted 
treatment. In addition, nanoparticles could be engineered ad hoc, not only to 
cross the BBB, but also to reach other organs or other specific targets as 
tumours. This would also allow treating diseases for which there are currently no 
treatments available due to inability of the drugs to target specific sites. 
In particular for LSDs, mainly due to deficits of the lysosomal enzymes, PLGA NPs 
probably represent the best vector, given the specific targeting of the NPs, which 
have been demonstrated to enter and accumulate right inside cell lysosomes.  
In general, a selective transport of big/heavy drugs to the CNS could greatly 
improve therapy for brain diseases, which have a very negative impact on 
patients, their families and society. 
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